



HU000026708T2

(19) **HU****MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 026 708**(13) **T2****EURÓPAI SZABADALOM**  
**SZÖVEGÉNEK FORDÍTÁSA**(21) Magyar ügyszám: **E 10 800456**(22) A bejelentés napja: **2010. 07. 14.**

(96) Az európai bejelentés bejelentési száma:

**EP 20100800456**

(97) Az európai bejelentés közzétételi adatai:

**EP 2453923 A2** **2011. 01. 20.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

**EP 2453923 B1** **2015. 11. 11.**(51) Int. Cl.: **A61K 47/42** (2006.01)**A61K 311/95** (2006.01)**A61K 311/98** (2006.01)**A61K 49/00** (2006.01)**C07K 14/00** (2006.01)**C07K 147/75** (2006.01)**A61K 51/12** (2006.01)**A61K 47/48** (2006.01)**A61K 38/16** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

**PCT/US 10/041924**

(87) A nemzetközi közzétételi szám:

**WO 11008823**

(30) Elsőbbségi adatok:

**225412 P****2009. 07. 14.****US**

(72) Feltaláló(k):

**CURRAN, Geoffry L., Rochester Minnesota 55906 (US)****SARKAR, Gobinda, Rochester Minnesota 55902 (US)****PODUSLO, Joseph F., Rochester Minnesota 55901 (US)****JENKINS, Robert B., Rochester Minnesota 55902 (US)****LOWE, Val J., Rochester Minnesota 55906 (US)****MAHLUM, Eric W., Rochester Minnesota 55901 (US)**

(73) Jogosult(ak):

**MAYO FOUNDATION FOR MEDICAL****EDUCATION AND RESEARCH, Rochester, MN****55905 (US)**

(74) Képviselő:

**Danubia Szabadalmi és Jogi Iroda Kft.,****Budapest**

(54)

**Hatóanyagok véragygáton történő, peptidmediált, nem kovalens átjuttatása**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 453 923 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**11.11.2015 Bulletin 2015/46**

(21) Application number: **10800456.5**

(22) Date of filing: **14.07.2010**

(51) Int Cl.:  
**A61K 47/42** <sup>(2006.01)</sup> **A61K 31/198** <sup>(2006.01)</sup>  
**A61K 31/195** <sup>(2006.01)</sup> **A61K 38/16** <sup>(2006.01)</sup>  
**A61K 49/00** <sup>(2006.01)</sup> **C07K 14/775** <sup>(2006.01)</sup>  
**A61K 51/12** <sup>(2006.01)</sup> **A61K 47/48** <sup>(2006.01)</sup>  
**C07K 14/00** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2010/041924**

(87) International publication number:  
**WO 2011/008823 (20.01.2011 Gazette 2011/03)**

(54) **PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD BRAIN BARRIER**

PEPTIDVERMITTELTE NICHT-KOVALENTE VERABREICHUNG VON WIRKSTOFFEN ÜBER DIE BLUT-HIRN-SCHRANKE

ADMINISTRATION NON COVALENTE D'AGENTS ACTIFS PAR L'INTERMÉDIAIRE D'UN PEPTIDE À TRAVERS LA BARRIÈRE HÉMATO-ENCÉPHALIQUE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO SE SI SK SM TR**

(30) Priority: **14.07.2009 US 225412 P**

(43) Date of publication of application:  
**23.05.2012 Bulletin 2012/21**

(73) Proprietor: **MAYO FOUNDATION FOR MEDICAL  
EDUCATION AND RESEARCH  
Rochester, MN 55905 (US)**

(72) Inventors:  
• **CURRAN, Geoffry L.**  
Rochester  
Minnesota 55906 (US)  
• **SARKAR, Gobinda**  
Rochester  
Minnesota 55902 (US)  
• **PODUSLO, Joseph F.**  
Rochester  
Minnesota 55901 (US)  
• **JENKINS, Robert B.**  
Rochester  
Minnesota 55902 (US)

• **LOWE, Val J.**  
Rochester  
Minnesota 55906 (US)  
• **MAHLUM, Eric W.**  
Rochester  
Minnesota 55901 (US)

(74) Representative: **Conroy, John et al**  
**Fish & Richardson P.C.**  
**Highlight Business Towers**  
**Mies-van-der-Rohe-Straße 8**  
**80807 München (DE)**

(56) References cited:  
**US-A- 5 168 045** **US-A1- 2004 229 219**  
**US-A1- 2006 198 833** **US-A1- 2007 086 981**  
**US-A1- 2008 213 185** **US-A1- 2010 119 528**

• **MOUSAZADEH MOHAMMAD ET AL: "Gene  
delivery to brain cells with apoprotein E derived  
peptide conjugated to polylysine (apoEdp-PLL).",  
JOURNAL OF DRUG TARGETING APR 2007, vol.  
15, no. 3, April 2007 (2007-04), pages 226-230,  
XP008158771, ISSN: 1061-186X**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 453 923 B1**

- |                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>• GOBINDA SARKAR ET AL: "A Carrier for Non-Covalent Delivery of Functional Beta-Galactosidase and Antibodies against Amyloid Plaques and IgM to the Brain", PLOS ONE, vol. 6, no. 12, 21 December 2011 (2011-12-21), page e28881, XP055047546, DOI: 10.1371/journal.pone.0028881</li></ul> | <ul style="list-style-type: none"><li>• ERIC MAHLUM ET AL.: 'Engineering a noncarrier to a highly efficient carrier peptide for noncovalently delivering biologically active proteins into human cells' ANAL. BIOCHEM. vol. 365, 2007, pages 215 - 221, XP022077170</li></ul> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Description**

## TECHNICAL FIELD

5 **[0001]** This disclosure relates to carrier peptides, including compositions and methods of using the same. In particular, the disclosure relates to carrier peptides capable of delivering active agents across the blood-brain barrier and compositions and methods of using the same.

**BACKGROUND**

10

**[0002]** The blood-brain barrier (BBB) prevents most macromolecules (e.g., DNA, RNA, and polypeptides) and many small molecules from entering the brain. The BBB is principally composed of specialized endothelial cells with highly restrictive tight junctions, consequently, passage of substances, small and large, from the blood into the central nervous system is controlled by the BBB. This structure makes treatment and management of patients with neurological diseases and disorders (e.g., brain cancer and Alzheimer's disease) difficult as many therapeutic agents cannot be delivered across the BBB with desirable efficiency.

15

**[0003]** MOUSAZADEH MOHAMMAD ET AL, JOURNAL OF DRUG TARGETING, vol. 15, no. 3, 2007, pages 226-230, discloses methods of carrying genetic material across the blood brain barrier using the LDL receptor.

20

**[0004]** US 2004/229219 A1 discloses the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other respiratory diseases.


**SUMMARY**

25

**[0005]** The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules and imaging agents to transport the biologically active molecules and imaging agents across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules and imaging agents.

30

**[0006]** A carrier peptide, as described herein, includes the sequence:



or a pharmaceutically acceptable salt thereof, wherein:

35

X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3,

40

wherein the blood-brain barrier agent includes a polypeptide sequence having at least 80 % sequence identity to:

L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13)

45

**[0007]** A hydrophilic amino acid (X) can be chosen from arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, tyrosine, or a combination thereof. For example, in some embodiments,  $X_n$  can comprise ten lysines and six arginines; six lysines and sixteen arginines; eight lysines, eight arginines, and eight histidines. In some embodiments, X is lysine.

50

**[0008]** The variable n is an integer ranging from 4 to 50 (e.g., 4, 6, 8, 10, 12, 16, 20, 24, 26, 28, 32, 36, 40, 42, 44, 48, and 50). In some embodiments, n is chosen from 4, 8, 12, 16, and 20. In some embodiments, n is 16. In some embodiments, m is 1.

**[0009]** Examples of a carrier peptide can include:

K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 19);

55

K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:20);

K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:21);

K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:22); and

K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:23).

**[0010]** Further provided herein is a complex, or a pharmaceutically acceptable salt thereof, having a biologically active molecule or an imaging agent associated with a carrier peptide, as described above. In some embodiments, the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide.

**[0011]** An imaging agent can be any chemical or substance which is used to provide the signal or contrast in imaging. For example, the imaging agent can be <sup>125</sup>I-IgG or magnevist. A biologically active molecule can include a polypeptide; oligonucleotide; plasmid; small molecule; antibody; antibody fragment; carbohydrate; polysaccharide; lipid; glycolipid; antigen; and antigenic peptide. In some embodiments, the biologically active molecule is chosen from a: polypeptide; oligonucleotide; and plasmid. An oligonucleotide can include a coding DNA sequence; antisense DNA sequence; mRNA, antisense RNA sequence; RNAi; and siRNA. In some embodiments, the biologically active molecule is a small molecule, for example, a therapeutic agent.

**[0012]** The carrier peptides and complexes of carrier peptides and biologically active agents or imaging agents have various uses and can be used in various methods. For example, provided herein is a method of transporting a biologically active molecule or imaging agent across the blood-brain barrier of a subject. The method can include administering to the subject a complex, or a pharmaceutically acceptable salt thereof, having the biologically active molecule or imaging agent associated with a carrier peptide.

**[0013]** The carrier peptide of the invention is useful in a method of treating a brain disorder in a subject. The method can include administering to the subject a complex, or a pharmaceutically acceptable salt thereof, having a biologically active agent associated with a carrier peptide. The brain disorder can be chosen from meningitis, epilepsy, multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, Parkinson's, progressive multifocal leukoencephalopathy, De Vivo disease, Alzheimer's disease, HIV Encephalitis, and cancer.

**[0014]** This disclosure further provides a method of imaging the central nervous system of a subject. The method can include administering to the subject a complex, or a pharmaceutically acceptable salt thereof, comprising an imaging agent associated with a carrier peptide; and imaging the central nervous system of the subject.

**[0015]** Pharmaceutical compositions are also disclosed. A pharmaceutical composition can include a complex, or a pharmaceutically acceptable salt thereof, having a biologically active molecule or imaging agent, a carrier peptide, and a pharmaceutically acceptable carrier.

**[0016]** Finally, kits are also provided. A kit can include a carrier peptide. In some embodiments, the kit further includes a biologically active molecule or an imaging agent.

**[0017]** The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

## DESCRIPTION OF DRAWINGS

### [0018]

**FIG 1** is a series of images illustrating the differences between delivery of Alexa-IgG complexed to K<sub>16</sub>ApoE (SEQ ID NO: 22) into brain and uncomplexed Alexa-IgG.

**FIG 2** illustrates the accumulation of radioactive IgG 4.1 in mouse brain aided by K<sub>16</sub>ApoE (SEQ ID NO: 22).

**FIG 3** shows delivery of K16APoE-mediated (SEQ ID NO: 22) beta-galactosidase in brain (Top) and in other organs (Bottom). In one experiment, beta-galactosidase was injected in mice mixed with (FIG. 3A') and without K16ApoE (SEQ ID NO: 22) (FIG. 3A), brain slices made six hours after injection were stained for enzyme activity (top). In a separate related experiment, slides were made from different organs and stained for beta-galactosidase activity after delivery without (FIG. 3B - G) and with K16ApoE (SEQ ID NO: 22) (FIG. 3B' - G'), B - brain; C - heart, D - kidney, E - lung, F - liver, G - spleen.

**FIG 4** shows the evaluation of K16ApoE-mediated (SEQ ID NO: 22) delivery of IgG (A) and IgM (B) in mice brains by microSPECT. Imaging was done at 1 hour intervals up to six hours, after which cardiac perfusion was performed, and final imaging carried out 30 minutes after perfusion. Left bars - with K16ApoE (SEQ ID NO: 22); Right bars - no K16ApoE (SEQ ID NO: 22).

**FIG. 5** illustrates labeling of amyloid plaques with a plaque-specific antibody delivered via K16ApoE (SEQ ID NO: 22) in brains of mice models of Alzheimer's disease. Two mice with Alzheimer's disease were used: one represented by A, C and E, while the other is represented by B, D and F. A, C and E represent adjacent brain sections from one mouse, whereas B, D and F represent adjacent brain sections from another mouse. A, B - thioflavine S staining; C, D - immunostaining to identify plaques using the 4G8 as the primary antibody, and an anti-mouse antibody as the

secondary antibody; E, F - immunostaining using the secondary antibody only. The 4G8 IgG was injected in the first mouse (left panel) without K16ApoE (SEQ ID NO: 22), while the second mouse (right panel) received injection of the IgG mixed with K16ApoE (SEQ ID NO: 22).

**FIG. 6** shows the evaluation of the integrity of the BBB after injection of K16ApoE (SEQ ID NO: 22). Each mouse (represented by A through G) received an injection of K16ApoE (SEQ ID NO: 22), followed by injection of  $\beta$ -galactosidase at the indicated times. Brain slices were made 4 hours after  $\beta$ -galactosidase injection and were followed by staining for activity of the enzyme. A -  $\beta$ -galactosidase was injected 1 minute after K16ApoE (SEQ ID NO: 22) injection. B -  $\beta$ -galactosidase was injected 5 minutes after K16ApoE (SEQ ID NO: 22) injection. C -  $\beta$ -galactosidase was injected 10 minutes after K16ApoE (SEQ ID NO: 22) injection. D -  $\beta$ -galactosidase was injected 30 minutes after K16ApoE (SEQ ID NO: 22) injection. E -  $\beta$ -galactosidase was injected 1 hour after K16ApoE (SEQ ID NO: 22) injection. F -  $\beta$ -galactosidase was injected 2 hours after K16ApoE (SEQ ID NO: 22) injection. G -  $\beta$ -galactosidase was injected 4 hours after K16ApoE (SEQ ID NO: 22) injection. H- positive control ( $\beta$ -galactosidase mixed with K16ApoE (SEQ ID NO: 22) was injected, brain slices were made 4 hours after the injection and proceeded for staining for enzyme activity).

**FIG. 7** demonstrates the need for chemical linking of the K16 (SEQ ID NO: 4) and the ApoE peptide moieties for non-covalent delivery across the BBB. Delivery of  $\beta$ -galactosidase in brain with K16 peptide (SEQ ID NO: 4) alone (A), with ApoE peptide only (B), with K16 peptide (SEQ ID NO: 4) + ApoE peptide (C), and with K16ApoE peptide (SEQ ID NO: 22) (D).

**FIG. 8** illustrates the testing mutant ApoE peptides for their potential as non-covalent transporters of proteins across the BBB. A - no peptide, no  $\beta$ -gal; B - K16ApoE (SEQ ID NO: 22) +  $\beta$ -gal; C - K16L3N7 (SEQ ID NO: 126) +  $\beta$ -gal; D - K16L3L20 (SEQ ID NO: 127) +  $\beta$ -gal; E - K16N7L20 (SEQ ID NO: 128) +  $\beta$ -gal.


**FIG. 9** shows a time course study of  $\beta$ -galactosidase delivery in mouse brain with K16ApoE (SEQ ID NO: 22). A-  $\beta$ -galactosidase, no peptide, 6h; B-  $\beta$ -galactosidase+ peptide, 1h; C-  $\beta$ -galactosidase+ peptide, 2h; D-  $\beta$ -galactosidase+ peptide, 5h; E-  $\beta$ -galactosidase+ peptide, 10h.

## DETAILED DESCRIPTION

**[0019]** The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules and imaging agents to transport the biologically active molecules and imaging agents across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules and imaging agents.

### Carrier Peptides

**[0020]** Provided herein are carrier peptides having the following sequence:



or a pharmaceutically acceptable salt, thereof, wherein:

X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3,

wherein the blood-brain barrier agent comprises a sequence having at least 80% (e.g., at least 85%; at least 90%; at least 92%; at least 95%; at least 98%; and at least 99%) sequence identity to:

L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13) ;

**[0021]** A hydrophilic amino acid can be chosen from: arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, tyrosine, and combinations and non-natural derivatives thereof. In some embodiments, a hydrophilic amino acid can be chosen from lysine or a non-natural lysine derivative, arginine or a non-natural arginine derivative, and combinations thereof. In some embodiments, the hydrophilic amino acid is lysine. Non-limiting examples of  $X_n$  can include KKKK (SEQ ID NO: 1); KKKKKKKK (SEQ ID NO:2); KKKKKKKKKKKK (SEQ ID NO:3); KKKKKKKKKKKKKKKK (SEQ ID NO:4); RRRR (SEQ ID NO:5); RRRRRRRR (SEQ ID NO:6); RRRRRRRRRRRR (SEQ ID NO:7); RRRRRRRRRRRRRRRR (SEQ ID NO:8); KRKR (SEQ ID NO:9); KKKR (SEQ ID NO: 10); KKKRRRKKRRR (SEQ ID NO: 11); and KKKRRRRRKKKKRRRR (SEQ ID NO:12).

**[0022]** The variable n is an integer ranging from 4 to 50 (e.g., 4, 6, 8, 10, 12, 16, 20, 24, 26, 28, 32, 36, 40, 42, 44, 48, and 50). For example, n can range from 4 to 20. In some embodiments, n is chosen from 4, 8, 12, 16, and 20. For example, n can be 16. In some embodiments, m is 1.

**[0023]** A blood-brain barrier agent, as used herein, is any polypeptide or non-polypeptide ligand that can cross the blood-brain barrier. In some embodiments, a blood-brain barrier agent has a cognate receptor on brain cells or can bind to such receptors. In some embodiments, the blood-brain barrier agent comprises a transferring-receptor binding site of a transferrin.

**[0024]** In some embodiments, the blood-brain barrier agent includes a polypeptide comprising the following sequence:

L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 13).

**[0025]** In some embodiments, the blood-brain barrier agent is less than 100 amino acids in length (e.g., less than 90 amino acids in length; less than 80 amino acids in length; less than 75 amino acids in length; less than 70 amino acids in length; less than 65 amino acids in length; less than 62 amino acids in length; less than 60 amino acids in length; less than 55 amino acids in length; less than 50 amino acids in length; and less than 45 amino acids in length).

**[0026]** "Percent sequence identity" refers to the degree of sequence identity between any given reference sequence, e.g., SEQ ID NO:13, and a candidate blood-brain barrier agent sequence. A candidate sequence typically has a length that is from 80 percent to 200 percent of the length of the reference sequence (e.g., 82, 85, 87, 89, 90, 93, 95, 97, 99, 100, 105, 110, 115, 120, 130, 140, 150, 160, 170, 180, 190, or 200 percent of the length of the reference sequence). A percent identity for any candidate nucleic acid or polypeptide relative to a reference nucleic acid or polypeptide can be determined as follows. A reference sequence (e.g., a nucleic acid sequence or an amino acid sequence) is aligned to one or more candidate sequences using the computer program ClustalW (version 1.83, default parameters), which allows alignments of nucleic acid or polypeptide sequences to be carried out across their entire length (global alignment). Chenna et al., Nucleic Acids Res., 31(13):3497-500 (2003).

**[0027]** ClustalW calculates the best match between a reference and one or more candidate sequences, and aligns them so that identities, similarities and differences can be determined. Gaps of one or more residues can be inserted into a reference sequence, a candidate sequence, or both, to maximize sequence alignments. For fast pairwise alignment of nucleic acid sequences, the following default parameters are used: word size: 2; window size: 4; scoring method: percentage; number of top diagonals: 4; and gap penalty: 5. For multiple alignment of nucleic acid sequences, the following parameters are used: gap opening penalty: 10.; gap extension penalty: 5.0; and weight transitions: yes. For fast pairwise alignment of peptide sequences, the following parameters are used: word size: 1; window size: 5; scoring method: percentage; number of top diagonals: 5; gap penalty: 3. For multiple alignment of peptide sequences, the following parameters are used: weight matrix: blosum; gap opening penalty: 10.; gap extension penalty: 0.5; hydrophilic gaps: on; hydrophilic residues: Gly, Pro, Ser, Asn, Asp, Gln, Glu, Arg, and Lys; residue-specific gap penalties: on. The ClustalW output is a sequence alignment that reflects the relationship between sequences. ClustalW can be run, for example, at the Baylor College of Medicine Search Launcher site ([searchlauncher.bcm.tmc.edu/multi-align/multi-align.html](http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.html)) and at the European Bioinformatics Institute site on the World Wide Web ([ebi.ac.uk/clustalw](http://ebi.ac.uk/clustalw)).

**[0028]** To determine percent identity of a candidate nucleic acid or amino acid sequence to a reference sequence, the sequences are aligned using ClustalW, the number of identical matches in the alignment is divided by the length of the reference sequence, and the result is multiplied by 100. It is noted that the percent identity value can be rounded to the nearest tenth. For example, 78.11, 78.12, 78.13, and 78.14 are rounded down to 78.1, while 78.15, 78.16, 78.17, 78.18, and 78.19 are rounded up to 78.2.

**[0029]** The variable m is an integer from 1 to 3. In some embodiments, m is 1.

**[0030]** In some embodiments, a carrier peptide can be chosen from:

K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 19);

K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:20);

K-K-K-K-K-K-K-K-K-K-L-R-V R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:21);

K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:22); and

K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:23).

#### Complexes

**[0031]** Also provided herein are complexes having a biologically active molecule or an imaging agent associated with

a carrier peptide as described herein. In some embodiments, the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide.

**[0032]** As used herein, a "biologically active molecule" includes any molecule which, if transported across the blood-brain barrier, can have a biological effect. Examples of biologically active molecules include polypeptides, which include functional domains of biologically active molecules, particular examples include growth factors, enzymes, transcription factors, toxins, antigenic peptides (as for vaccines), antibodies, and antibody fragments. For example, brain derived neurotrophic factor, fibroblast growth factor (e.g., (FGF)-2 or multiple FGFs), nerve growth factor, neurotrophin (e.g., NT-3 and NT-4/5), glial derived neurotrophic factor, ciliary neurotrophic factor, neurturin, neuregulins, interleukins, transforming growth factor (e.g., TGF- $\alpha$  and TGF- $\beta$ ), vasoactive intestinal peptide, epidermal growth factor (EGF), erythropoietin, hepatocyte growth factor, platelet derived growth factor, artemin, persephin, netrins, cardiotrophin-1, stem cell factor, midkine, pleiotrophin, bone morphogenic proteins, saposins, semaphorins, leukemia inhibitory factor, anti-A $\beta$ , anti-HER2, anti-EGF, anti-nogo A, anti-TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), anti- $\alpha$ -synuclein, anti-htt, anti-prion, anti-West Nile virus,  $\alpha$ L-iduronidase, iduronate-2-sulfatase, N-acetyl-galactosamine-6-sulfatase, arylsulfatase B, acid  $\alpha$ -glucosidase, and acid sphingomyelinase (See, Pardridge, W.M., *Bioconjug. Chem.* 19(7): 1327-38 2008). Additional examples of biologically active molecules include oligonucleotides, such as natural or engineered plasmids, coding DNA sequences, antisense DNA sequences, mRNAs, antisense RNA sequences, RNAs, and siRNAs; carbohydrates; lipids; and glycolipids.

**[0033]** Further examples of biologically active molecules include small molecules, including therapeutic agents, in particular those with low blood-brain barrier permeability. Some examples of these therapeutic agents include cancer drugs, such as daunorubicin and toxic chemicals which, because of the lower dosage that can be administered by this method, can now be more safely administered. For example, a therapeutic agent can include bevacizumab, irinotecan, zoledronate, and temozolomide.

**[0034]** In another embodiment, the therapeutic agent can include a broad-spectrum antibiotic (e.g., cefotaxime, ceftriaxone, ampicillin and vancomycin); an antiviral agent (e.g., acyclovir); acetazolamide; carbamazepine; clonazepam; clorazepate dipotassium; diazepam; divalproex sodium; ethosuximide; felbamate; fosphenytoin sodium; gabapentin; lamotrigine; levetiracetam; lorazepam; oxcarbazepine; phenobarbital; phenytoin; phenytoin sodium; pregabalin; primidone; tiagabine hydrochloride; topiramate; trimethadione; valproic acid; zonisamide; copaxone; tysabri; novantrone; donepezil HCL; rivastigmine; galantamine; memantine; levodopa; carbidopa; parlodel, permax, requip, mirapex; symmetrel; artane; cogentin; eldepryl; and deprenyl.

**[0035]** Numerous other examples of biologically active molecules will be apparent to the skilled artisan.

**[0036]** Yet another example of a biologically active molecule is an antigenic peptide. Antigenic peptides can be administered to provide immunological protection when imported by cells involved in the immune response. Other examples include immunosuppressive peptides (e.g., peptides that block autoreactive T cells, which peptides are known in the art).

**[0037]** Polypeptides from a few amino acids to about a thousand amino acids can be used. In some embodiments, the size range for polypeptides is from a few amino acids to about 250 amino acids (e.g., about 3 to about 250 amino acids; about 20 to about 250 amino acids; about 50 to about 250 amino acids; about 100 to about 250 amino acids; about 150 to about 250 amino acids; about 3 amino acids to about 200 amino acids; about 3 amino acids to about 150 amino acids; about 3 amino acids to about 175 amino acids; about 3 amino acids to about 125 amino acids; about 25 amino acids to about 200 amino acids; about 50 amino acids to about 150 amino acids; and about 75 amino acids to about 225 amino acids). For any molecule, size ranges can be up to about a molecular weight of about 1 million. In some embodiments, the size ranges up to a molecular weight of about 25,000, and in particular embodiments, the size ranges can be up to a molecular weight of about 3,000.

**[0038]** By "antisense" it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993 *Nature* 365, 566) interactions and alters the activity of the target RNA (for a review, see Stein and Cheng, 1993 *Science* 261, 1004; Agrawal et al., U.S. Pat. No. 5,591,721; Agrawal, U.S. Pat. No. 5,652,356). Typically, antisense molecules will be complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to a substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both.

**[0039]** RNA interference (RNAi) and short intervening RNA (siRNA) sequences can be used to modulate (e.g., inhibit) gene expression (see, e.g., Elbashir et al., 2001, *Nature*, 411, 494-498; and Bass, 2001, *Nature*, 411, 428-429; Bass, 2001, *Nature*, 411, 428-429; and Kreutzer et al., International PCT Publication No. WO 00/44895; Zernicka-Goetz et al., International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plaetinck et al., International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO 99/07409; and Li et al., International PCT Publication No. WO 00/44914). In one embodiment, a siRNA molecule comprises a double stranded RNA wherein one strand of



the RNA is complimentary to the RNA of interest. In another embodiment, a siRNA molecule comprises a double stranded RNA wherein one strand of the RNA comprises a portion of a sequence of an RNA of interest. In yet another embodiment, a siRNA molecule of the invention comprises a double stranded RNA wherein both strands of RNA are connected by a non-nucleotide linker. Alternately, a siRNA molecule of the invention comprises a double stranded RNA wherein both strands of RNA are connected by a nucleotide linker, such as a loop or stem loop structure.

**[0040]** The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules (i.e., molecules that contain an antigen binding site that specifically binds to a peptide). An antibody can be a monoclonal antibody, a polyclonal antibody, a humanized antibody, a fully human antibody, a single chain antibody, a chimeric antibody, or a fragment thereof. The term "antibody fragment" of a full length antibody refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to a target of interest.

**[0041]** An imaging agent, as used herein, can be any chemical or substance which is used to provide the signal or contrast in imaging. The signal enhancing domain can be an organic molecule, metal ion, salt or chelate, particle (particularly iron particle), or labeled peptide, protein, polymer or liposome.

**[0042]** In some embodiments, the imaging agent is a physiologically compatible metal chelate compound consisting of one or more cyclic or acyclic organic chelating agents complexed to one or more metal ions with atomic numbers 21-29, 42, 44, or 57-83.


**[0043]** For x-ray imaging, the imaging agent may consist of iodinated organic molecules or chelates of heavy metal ions of atomic numbers 57 to 83. In some embodiments, the imaging agent is  $^{125}\text{I}$ -IgG. Examples of suitable compounds are described in M. Sovak, ed., "Radiocontrast Agents," Springer-Verlag, pp.23-125 (1984) and U.S. Pat. No. 4,647,447.

**[0044]** For ultrasound imaging, the imaging agent can consist of gas-filled bubbles such as Albunex, Echovist, or Levovist, or particles or metal chelates where the metal ions have atomic numbers 21-29, 42, 44 or 57-83. Examples of suitable compounds are described in Tyler et al., Ultrasonic Imaging, 3, pp. 323-29 (1981) and D. P. Swanson, "Enhancement Agents for Ultrasound: Fundamentals," Pharmaceuticals in Medical Imaging, pp. 682-87. (1990).


**[0045]** For nuclear radiopharmaceutical imaging or radiotherapy, the imaging agent can consist of a radioactive molecule. In some embodiments, the chelates of Tc, Re, Co, Cu, Au, Ag, Pb, Bi, In, and Ga can be used. In some embodiments, the chelates of Tc-99m can be used. Examples of suitable compounds are described in Rayudu GVS, Radiotracers for Medical Applications, I, pp. 201 and D. P. Swanson et al., ed., Pharmaceuticals in Medical Imaging, pp. 279-644 (1990).

**[0046]** For ultraviolet/visible/infrared light imaging, the imaging agent can consist of any organic or inorganic dye or any metal chelate.


**[0047]** For MRI, the imaging agent can consist of a metal-ligand complex of a paramagnetic form of a metal ion with atomic numbers 21-29, 42, 44, or 57-83. In some embodiments, the paramagnetic metal is chosen from: Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III), Ho(III), Er(III) and Eu(III). Many suitable chelating ligands for MRI agents are known in the art. These can also be used for metal chelates for other forms of biological imaging. For example, an imaging agent can include:




Magnevist  
gadopentetate dimeglumine  
DTPA



Dotarem  
gadoterate meglumine  
DOTA



Omniscan  
gadobutamide  
DTPA-BMA



ProHance  
gadoteridol  
HP-DO3A

**[0048]** "Associated with", as used herein, is meant that the biologically active molecule or imaging agent is conjugated to the carrier peptide in such a manner that when the carrier peptide crosses the blood-brain barrier, the molecule or agent is also imported. In certain embodiments, the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide. For example, the biologically active molecule and the carrier peptide may be associated through electrostatic interactions. In other embodiments, the carrier peptide may be covalently bound, either directly or indirectly (e.g., through a linker), to the biologically active molecule or imaging agent.

**[0049]** A linker can be any moiety suitable for linking a carrier peptide to a biologically active molecule. A linker can be bound at the C-terminus, the N-terminus, or both, of a carrier peptide. Additionally, a linker can be bound to the side chain of a carrier peptide. If a carrier peptide is bound to multiple linkers, each linker can be different. A linker can be covalently linked to a side chain of an amino acid, e.g., lysine, glutamine, cysteine, methionine, glutamate, aspartate, asparagine.

**[0050]** In some embodiments an amino acid side chain can serve as the linker. For example the epsilon amino group ( $\epsilon$ -NH<sub>2</sub>) can be used to conjugate to a carrier for instance through an amide or thiourea linkage. Similarly the delta amino group of ornithine (orn), the gamma amino group of diaminobutyric acid (dab), or the beta amino group of diamino propionic acid (dpr) can also act as linkers. These amino acids may be at the C- or N-terminus of the carrier peptide or they may be positioned within the carrier peptide sequence.

**[0051]** The complex composed of a biologically active molecule or imaging agent and a carrier peptide can be prepared by any method known by those having ordinary skill in the art. In some embodiments, the carrier peptide and the biologically active molecule or imaging agent are combined, incubated at room temperature, and then used. For example, solutions can be prepared of the delivery peptide (K16ApoE (SEQ ID NO: 22)) and IgG in PBS (phosphate buffered saline) or OptiMem (commercially available) or cell culture media without serum in desired concentrations. The delivery peptide and IgG can be mixed in the desired ratios and then incubated at room temperature for 30-60 minute. Following incubation, the mixture is ready for injection/delivery.

**[0052]** Combinations of the biologically active molecule and the carrier peptide can be prepared at a variety of molar ratios. For example, a molar ratio of biologically active molecule to carrier peptide can range from about 1:1 to about 1:200 (e.g., 1:2; 1:5; 1:8; 1:10; 1:25; 1:30; 1:40; 1:45; 1:50; 1:60; 1:65; 1:70; 1:75; 1:80; 1:90; 1:100; 1:125; 1:135; 1:145; 1:150; 1:175; and 1:190). In some embodiments, a molar excess of carrier peptide to biologically active molecule is used. For example, the molar ratio of biologically active molecule to carrier peptide can range from about 1:20 to about 1:100 (e.g., 1:50 to about 1:90). In some cases, the ratio can be 1:70.

**[0053]** The term "pharmaceutically-acceptable salt" refers to salts which possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which may render them useful, for example in processes of synthesis, purification or formulation of compounds described herein. In general the useful properties of the compounds described herein do not depend critically on whether the compound is or is not in a salt form, so unless clearly indicated otherwise (such as specifying that the compound should be in "free base" or "free acid" form), reference in the specification to a carrier peptide or a complex comprising a carrier peptide should be understood as encompassing salt forms of the compound, whether or not this is explicitly stated.

**[0054]** Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic,  $\beta$ -hydroxybutyric, salicylic, galactaric and galacturonic acid. Examples of pharmaceutically unacceptable acid addition salts include, for example, perchlorates and tetrafluoroborates.

**[0055]** Suitable pharmaceutically acceptable base addition salts include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, *N,N'*-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Examples of pharmaceutically unacceptable base addition salts include lithium salts and cyanate salts.

**[0056]** All of these salts may be prepared by conventional means from the corresponding carrier peptide or complex by reacting, for example, the appropriate acid or base with a carrier peptide or complex as described herein. Preferably the salts are in crystalline form, and preferably prepared by crystallization of the salt from a suitable solvent. A person skilled in the art will know how to prepare and select suitable salt forms for example, as described in Handbook of Pharmaceutical Salts: Properties, Selection, and Use By P. H. Stahl and C. G. Wermuth (Wiley-VCH 2002).

*Methods of Use*

**[0057]** Also envisaged herein are methods of using carrier peptides to transport a biologically active molecule or imaging agent across the blood-brain barrier of a subject. The method can include administering to the subject a complex having a biologically active molecule or imaging agent associated with a carrier peptide, or a pharmaceutically acceptable salt, as described herein.

**[0058]** A subject can include both mammals and non-mammals. Mammals include, for example, humans; nonhuman primates, e.g. apes and monkeys; cattle; horses; sheep; rats; mice; pigs; and goats. Non-mammals include, for example, fish and birds.

**[0059]** Transporting a biologically active molecule can include importing the molecule across the blood-brain barrier.

**[0060]** Further envisaged herein is a method of treating a brain disorder in a subject. The method can include administering to the subject a complex comprising a biologically active agent associated with a carrier peptide, as described herein. In some examples, the biologically active molecule is a therapeutic agent. In some examples, the brain disorder is chosen from: meningitis, epilepsy, multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, Parkinson's, progressive multifocal leukoencephalopathy, De Vivo disease, Alzheimer's disease, HIV Encephalitis, and cancer.

**[0061]** In some examples, the brain disorder is a brain cancer, for example astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; or a cancer of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.

**[0062]** This disclosure also provides a method of imaging the central nervous system of a subject. In some embodiments, the method can include administering to the subject a complex comprising an imaging agent associated with a carrier peptide, as described herein, and imaging the central nervous system of the subject.

**[0063]** The complex can be administered by any route, e.g., IV, intramuscular, SC, oral, intranasal, inhalation, transdermal, and parenteral.

**[0064]** The complex can be formulated with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice. The complex may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations. See Alphonso Gennaro, ed., *Remington's Pharmaceutical Sciences*, 18th Edition (1990), Mack Publishing Co., Easton, PA. Suitable dosage forms may comprise, for example, tablets, capsules, solutions, parenteral solutions, troches, suppositories, or suspensions.

**[0065]** For parenteral administration, the complex may be mixed with a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol. Solutions for parenteral administration preferably contain a water soluble salt of the complex. Stabilizing agents, antioxidant agents and preservatives may also be added. Suitable antioxidant agents include sulfite, ascorbic acid, citric acid and its salts, and sodium EDTA. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorbutanol. The composition for parenteral administration may take the form of an aqueous or non-aqueous solution, dispersion, suspension or emulsion.

**[0066]** For oral administration, the complex may be combined with one or more solid inactive ingredients for the preparation of tablets, capsules, pills, powders, granules or other suitable oral dosage forms. For example, the complex may be combined with at least one excipient such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents absorbents or lubricating agents.

**[0067]** The specific dose of a complex will, of course, be determined by the particular circumstances of the individual patient including the size, weight, age and sex of the patient, the nature and stage of the disease being treated, the aggressiveness of the disease disorder, and the route of administration of the compound.

*Pharmaceutical compositions*

**[0068]** Provided herein are pharmaceutical compositions comprising a biologically active molecule or imaging agent associated with a carrier peptide. In some embodiments, the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide.

**[0069]** The pharmaceutical compositions provided herein contain a biologically active molecule or imaging agent associated with a carrier peptide in an amount that results in transportation of the biologically active molecule or imaging agent across the blood-brain barrier, and a pharmaceutically acceptable carrier. Pharmaceutical carriers suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.

**[0070]** The compositions can be, in one embodiment, formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration and intraperitoneal injection, as well as transdermal patch preparation, dry powder inhalers, and ointments (see, e.g., Ansel *Introduction to Pharma-*

ceutical Dosage Forms, Fourth Edition 1985, 126).

**[0071]** The concentration of the biologically active molecule or imaging agent associated with a carrier peptide in the pharmaceutical composition will depend on absorption, inactivation and excretion rates of the compounds, the physicochemical characteristics of the compounds, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.

**[0072]** The pharmaceutical composition may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

**[0073]** The pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are, in one embodiment, formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms as used herein refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes and individually packaged tablets or capsules. Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit-doses which are not segregated in packaging.

**[0074]** Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.

**[0075]** Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975.

**[0076]** Dosage forms or compositions containing a biologically active molecule or imaging agent associated with a carrier peptide in the range of 0.005% to 100% with the balance made up with a non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art. The contemplated compositions may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 75-85%.

#### *Kits*

**[0077]** Also provided herein are kits. Typically, a kit includes a carrier peptide, as described previously. In some embodiments, a kit includes a carrier peptide and a biologically active molecule and/or imaging agent. In certain embodiments, a kit can include one or more delivery systems, e.g., for a biologically active molecule, imaging agent, carrier peptide, or any combination thereof, and directions for use of the kit (e.g., instructions for administering to a subject). In certain embodiments, a kit can include a biologically active molecule and/or an imaging agent, a carrier peptide, and/or a complex of a biologically active molecule or imaging agent and a carrier peptide. In some embodiments, the kit can include a carrier peptide and a label that indicates that the contents are to be administered to a subject with a biologically active molecule or imaging agent.

## EXAMPLES

### *General*

#### **Materials:**

**[0078]** All mice used (B6SJLF1) were female and were purchased from the Jackson Laboratories. Mice were maintained

and used following an IRB-approved protocol. Bacterial  $\beta$ -galactosidase was purchased from Calbiochem (Catalog # 345788). Human IgG and IgM were purchased from Sigma (Product Numbers I 4506 and I8260 respectively). The 4G8 monoclonal antibody (cat# SIG-39220) was purchased from Covance (Emeryville, CA). LDL receptor antibody was from abcam (Cat # ab30532).

**[0079]** All peptides were synthesized at the Mayo Proteomic Core Facility.

**[0080] Preparation of peptide-protein complex for delivery in the brain:** Required amount of the peptide and protein were mixed in a final volume of 300  $\mu$ L PBS (phosphate buffered saline), and incubated at room temperature for 60 minutes. The mixture was vortexed for a few seconds, every fifteen minutes during the incubation period.

**[0081]** The mixture was injected intravenously as a bolus into the lumen of the femoral vein. This was accomplished using a heat pulled PE50 catheter. At the conclusion of the experiment, the mouse was euthanized with a lethal dose of sodium pentobarbital. Each mouse was perfused with 10 mL PBS. This perfusion was accomplished through the standard trans cardiac method. The brain was removed from the skull and positioned to make an initial coronal slice at -2.0 mm bregma. Subsequently, 25  $\mu$ m coronal sections were cut on a cryostat and placed on charged slides for staining of  $\beta$ -galactosidase activity.

**[0082] Staining for beta-galactosidase enzyme activity:** Evaluation of  $\beta$ -galactosidase enzymatic activity was accomplished by an initial 15 minute fixation of the brain sections in 0.25% glutaraldehyde. The slides were washed with 3 changes of PBS for 5 minutes each and then rinsed in distilled water for 5 minutes. The brain sections were incubated in X-Gal (0.2%) working solution, pH 7.38, for 18 hours at 37°C in covered containers. Following this incubation the sections were dehydrated and coverslips were applied.

**[0083] Imaging by microSPECT:** Micro SPECT/CT experiments were conducted on a Gamma Medica X SPECT System (GE Healthcare). Human IgG (Sigma) and IgM (Sigma) were labeled to a high specific activity using the Chloramine-T method. 80  $\mu$ g (500  $\mu$ Ci) of each immunoglobulin (corresponds to 0.53 nanomole of IgG and 0.13 nanomole of IgM assuming molecular weights of 150 Kd and 600 Kd for IgG and IgM, respectively) was mixed with 70-fold molar excess of K16ApoE (SEQ ID NO: 22) (as required for experiment) for 1 hour at room temperature and was administered in each mouse through the use of a catheter in the femoral vein. Immediately subsequent to the intravenous bolus injection, the mice were imaged every hour for a total of 6 hours. At the completion of the 6 hour time point, each mouse was euthanized and the systemic blood supply was transcardially perfused with 10 mL phosphate buffered saline, and imaged after 30 minutes.

#### Example 1 - Delivery of radiolabeled IgG across the BBB

**[0084]** The delivery of radiolabeled IgG across the BBB in different brain regions in mice with and without the peptide K<sub>16</sub>ApoE (SEQ ID NO:22) was evaluated. In addition, the integrity of the BBB after delivery of IgG with K<sub>16</sub>ApoE (SEQ ID NO: 22) was examined. 3  $\mu$ mol of <sup>125</sup>I-IgG were mixed with varying amounts of the peptide K<sub>16</sub>ApoE (SEQ ID NO: 22) (0 - 55  $\mu$ mol), and the mixture injected intravenously into the mice. <sup>131</sup>I-IgG not complexed with the peptide was injected into the same animals at 59 minutes and allowed to circulate for 1 minute subsequent to the initial femoral vein injection of <sup>125</sup>I-IgG+K<sub>16</sub>ApoE (SEQ ID NO: 22). Uptake of <sup>125</sup>I-IgG and <sup>131</sup>I-IgG were measured in different areas of the brain after 60 minutes.

Table 1.

| PSx10 <sup>6</sup> (ml/g/s) | IgG, 3 $\mu$ mol | +ApoE, 8 $\mu$ mol | +ApoE, 16 $\mu$ mol | +ApoE, 32 $\mu$ mol | +ApoE, 55 $\mu$ mol |
|-----------------------------|------------------|--------------------|---------------------|---------------------|---------------------|
| Cortex                      | 0.13+- 0.02      | 0.30               | 0.47                | 9.58                | 15.30               |
| Caudate                     | 0.09+-0.01       | 0.35               | 0.86                | 16.65               | 22.60               |
| Hippo                       | 0.17+-0.02       | 0.58               | 1.05                | 12.52               | 20.90               |
| Thalamus                    | 0.13+-0.02       | 0.29               | 1.37                | 19.60               | 21.00               |
| Brainstem                   | 0.20+-0.02       | 0.45               | 1.64                | 22.90               | 18.40               |
| Cerebellum                  | 0.15 +-0.02      | 0.48               | 0.72                | 13.43               | 21.60               |
| <b>Vp (ul/g)</b>            |                  |                    |                     |                     |                     |
| Cortex                      | 13.53+-0.98      | 21.39              | 21.22               | 16.41               | 25.59               |
| Caudate                     | 8.53+-0.52       | 14.44              | 11.67               | 12.89               | 20.10               |
| Hippo                       | 15.13+-2.35      | 17.49              | 16.95               | 12.67               | 21.83               |
| Thalamus                    | 13.79+-1.09      | 19.96              | 21.00               | 18.34               | 26.92               |

(continued)

| Vp (ul/g)      |             |       |       |       |       |
|----------------|-------------|-------|-------|-------|-------|
| Brainstem      | 22.32+-1.51 | 19.02 | 31.50 | 20.54 | 34.60 |
| Cerebellum     | 20.79+-1.24 | 21.28 | 23.74 | 19.79 | 24.31 |
| N (no of mice) | 4           | 2     | 2     | 2     | 1     |

PS values reflect the amount of  $^{125}\text{I}$ -IgG that has crossed the BBB, whereas Vp values indicate the amount of  $^{131}\text{I}$ -IgG at the BBB but which has not crossed the BBB.

**[0085]** As shown in Table 1, the PS values with IgG alone are very small for all the brain regions, indicating very little transport of the IgG across the BBB. However, the values increased significantly (~100-fold at 55  $\mu\text{mol}$  of  $\text{K}_{16}\text{ApoE}$  (SEQ ID NO: 22)) with increasing amounts of the delivery peptide.

**[0086]** On the other hand, the Vp values remained virtually unchanged in all the brain regions examined, indicating  $^{131}\text{I}$  IgG failed to cross the BBB (since it was not complexed with the peptide), and attesting to the notion that the BBB was not damaged due to prior exposure to the peptide (during delivery of  $^{125}\text{I}$ -IgG complexed with  $\text{K}_{16}\text{ApoE}$  (SEQ ID NO: 22)).

#### *Example 2 - Delivery of alexa-IgG assisted by $\text{K}_{16}\text{ApoE}$ (SEQ ID NO: 22) into brain*

**[0087]** In this experiment, AlexalgG488 was injected into mice with or without mixing with  $\text{K}_{16}\text{ApoE}$  peptide (SEQ ID NO: 22). Brain sections were made 1 hour after delivery. As shown in FIG. 1, the complexed agent shows significantly brighter contrast and enhancement of brain structures compared to the uncomplexed AlexalgG488.

#### *Example 3 - Delivery of ApoE peptide (without $\text{K}_{16}$ moiety (SEQ ID NO: 4)) across the BBB and binding of peptide to LDL receptors*

**[0088]** The experiments will evaluate the ApoE peptide (without the  $\text{K}_{16}$  moiety (SEQ ID NO: 4)) crossing of the BBB and whether it will bind/localize to LDL receptors (LDLR) expressed in the brain. An FITC-labeled ApoE peptide will be synthesized and injected into mice. Brain specimens will be collected after 1 hour following injection, and slides will be prepared with brain sections of 10 microns thickness. The slides will be stained with antibody against LDLR and evaluated to determine whether the signals for LDLR and the ApoE peptide are co-localized.

#### *Example 4 - Location of $\text{K}_{16}\text{ApoE}$ (SEQ ID NO: 22) following delivery across the BBB*

**[0089]** The experiments will determine the location of protein delivery by the carrier peptide ( $\text{K}_{16}\text{ApoE}$  (SEQ ID NO: 22)) within the brain.  $\text{K}_{16}\text{ApoE}$  (e.g., SEQ ID NO: 22) + Alexa-IgG (green fluorescence) conjugate will be prepared by mixing solutions of each at the desired concentrations and incubating the mixture at room temp for 30 minutes. The complex will be injected into mice and brain specimens collected after 1 hour. Slides will be prepared as above, and immunostained for GFAP, calbindin and neuregulin. If co-localization of IgG and GFAP is seen, such a result may indicate that the delivered IgG reached the astrocytes. Co-localization of IgG and calbindin or neuregulin, however, may indicate that the delivered IgG reached the neurons.

#### *Example 5 - Compromised integrity of the BBB by $\text{K}_{16}\text{ApoE}$ (SEQ ID NO: 22)*

**[0090]** These experiments will evaluate whether the  $\text{K}_{16}\text{ApoE}$  (e.g., SEQ ID NO: 22), alone or following formation of a complex, compromises the integrity of the BBB. A complex with  $\text{K}_{16}\text{ApoE}$  (SEQ ID NO: 22) + AlexaRedIgG will be prepared and injected into mice. After 1 hour uncomplexed AlexaGreenIgG will be injected. Brain specimens will be collected 1 hour after the second injection, and slides will be prepared using 10 micron sections. The sections will be visualized using confocal microscopy. In other mice, the reverse the experimental approach will be implemented using AlexaGreenIgG complexed with  $\text{K}_{16}\text{ApoE}$  (SEQ ID NO: 22) and uncomplexed AlexaRedIgG. If the peptide does not compromise the BBB, then only red fluorescence will be seen in cells in the brain. However, if the peptide does compromise the BBB, then both red and green fluorescence will be seen, and *vice versa*.

*Example 6 - Evaluation of microSPECT*

**[0091]** A microSPECT machine can image and quantify radioactivity in various tissues in live animals under anesthesia. If K<sub>16</sub>ApoE (SEQ ID NO: 22) indeed carries a protein (radioactive) across the BBB, then there should be more radioactivity in the brain of a mice injected with such a peptide-protein complex than in the brain of a mice injected with the radioactive protein alone.

**[0092]** IgG 4.1 (an antibody against the amyloid precursor protein (APP)) was radioiodinated. IgG4.1 alone or previously complexed with K<sub>16</sub>ApoE (SEQ ID NO:22) was injected in a number of mice. The mice were anesthetized and the brain was imaged with a microSPECT machine at 1 hour intervals. Perfusion was done for some mice after six hours of quantitative imaging followed by imaging after 30 minutes.

**[0093]** The radioactivity measured at each time point for each mice was plotted against time (FIG. 2). Seven animals were used in total, they are numbered M3-M9. M3 and M4 mice were not perfused. Two mice (M5 and M7) receiving IgG 4.1 were perfused after 6 hours of imaging, and three mice (M6, M8 and M9) receiving the IgG complexed with the delivery peptide were perfused after 6 hours of imaging followed by imaging at 6.5 hours.

**[0094]** It is clear from the data presented in FIG. 2 that ~2-fold more radioactivity was registered in the brains of mice delivered with the IgG complexed with the peptide than the IgG alone. This difference increased to nearly 5-fold when the animals were perfused.

**[0095]** Radioactivity in the brains of mice receiving IgG alone indicated IgG molecules were retained in the capillaries. Increased accumulation of radioactivity in the brains of mice receiving the IgG complexed with the delivery peptide indicated IgGs were present in the capillaries as well as having crossed the BBB and retained in the brain. If the IgG crosses the BBB and is retained in brain cells, then perfusion of the brains should eliminate IgGs in the capillaries but IgGs that have crossed the BBB should still be retained, which is essentially seen for mice M6, M8 and M9, providing strong indication that the peptide helps carry the protein (IgG) through the BBB into the brain.

*Example 7 - Delivery of a protein across the BBB*

**[0096]** To evaluate the potential of K16ApoE (SEQ ID NO: 22) for delivering a protein across the BBB, the enzyme  $\beta$ -galactosidase was injected in mice with or without prior mixing with K16ApoE (SEQ ID NO: 22) (at a protein to peptide molar ratio of 1:70). The experiment was repeated more than a dozen times. In this series of experiments, intense  $\beta$ -galactosidase activity was observed in mice brain when the enzyme-peptide mix was injected and brain slices were prepared for enzyme activity staining 6 hours after injection, whereas no activity was seen when the enzyme was injected alone (**FIG. 3A**). High-magnification scans of the images of  $\beta$ -galactosidase-stained sections in the brain showed that the enzyme was delivered in virtually every area of the brain, and stained both astrocytes and neurons, however, pyramidal cells in the hippocampus showed much weaker staining for  $\beta$ -galactosidase activity compared to cells in other areas of the brain. The weak  $\beta$ -galactosidase activity staining in the pyramidal cells does not appear to be due to low expression of LDLR in mouse hippocampus since cells in this region display strong immunohistochemical staining for the receptor. It is speculated that either X-gal or 5-bromo-4-chloroindole or both somehow leach out of this region faster than other regions of the brain resulting to a faint signal for  $\beta$ -galactosidase activity.

**[0097]** To assess if the delivery of  $\beta$ -galactosidase in the brain via K16ApoE (SEQ ID NO: 22) is LDLR-mediated,  $\beta$ -galactosidase staining in liver, brain, kidney, heart and lung after injection of the enzyme with and without mixing with K16ApoE (SEQ ID NO: 22) was also evaluated. The most intense staining was observed in liver and brain, followed by staining in lung, heart and kidney (**FIG. 3B-G**). This pattern of uptake of beta-galactosidase by K16ApoE (SEQ ID NO: 22) in various organs approximately follows the pattern of reported LDLR expression pattern suggesting that delivery of  $\beta$ -galactosidase through K16ApoE (SEQ ID NO: 22) is LDLR-mediated.

*Example 8 - Delivery of IgG and IgM using K16ApoE (SEQ ID NO: 22)*

**[0098]** Since many potentially therapeutic proteins against brain-associated disorders are immunoglobulins, delivery of IgG and IgM through K16ApoE (SEQ ID NO: 22) in mouse brain was evaluated by micro-single photon emission computed tomography (microSPECT) imaging. For this, radioiodinated human IgG (Sigma, product# I 4506) and human IgM (Sigma, product # I 8260) were mixed with K16ApoE (SEQ ID NO: 22) and injected intravenously. Anesthetized animals were then subjected to imaging for 6 hours at 1 hour interval. Cardiac perfusion was then performed, after which final imaging was done at 30 minutes post-perfusion. Results from these experiments provide a number of indications (**FIG. 4**): First, it appears that peak delivery of both IgG and IgM into brain happens around 2 hours post-injection of the peptide-protein mix, after which uptake of the proteins in the brain remains relatively unchanged up to 6 hours (maximum time point tested). Second, cardiac perfusion appears to remove most of the radioactive protein in the vasculature, concomitantly increasing the difference between apparent brain-uptake of the protein with and without the carrier peptide (~ 5-fold). Finally, the results suggest that about 1% of the injected immunoglobulins are transported into the brain by

K16ApoE (SEQ ID NO: 22) under the experimental condition. It is interesting to note that the extent of delivery of the radiolabeled IgG and IgM into kidney, liver/spleen and heart remained virtually unchanged irrespective of whether the proteins were delivered with or without the carrier peptide. Cardiac perfusion also did not change the accumulation of radioactivity in these organs, implying that transport of proteins in these organs does not depend upon crossing of a biological barrier.

*Example 9 - Efficacy of delivered therapeutic*

**[0099]** For its activity,  $\beta$ -galactosidase does not need to bind with any molecular entity in the brain. However, for all therapeutic purposes, the delivered molecule in the brain must be able to recognize and bind with its cognate target molecule. To test this premise, an antibody against amyloid beta peptide (4G8 from Cavance) was delivered via K16ApoE (SEQ ID NO: 22) in the brains of mice which model for Alzheimer's disease. This antibody is known to recognize amyloid beta plaques. The results indicate that the antibody delivered in this manner labeled the amyloid plaques in the brain of these mice as well as identified the plaques with the antibody through standard immunohistochemistry (**FIG. 5**). Similar results were also obtained with another antibody (4.1 IgG, 32) known to label these plaques.

*Example 10 - Transportation of protein without damage to BBB*

**[0100]** A transporter that efficiently carries a protein in the brain should not do so by impairing the integrity of the BBB. To evaluate if K16ApoE (SEQ ID NO: 22) impairs the integrity of the BBB, the peptide was first injected intravenously, then injected  $\beta$ -galactosidase at different time intervals. The control mice received the enzyme mixed with the peptide. Mice were perfused and sacrificed 6 hours after  $\beta$ -galactosidase injection, brain slices were made and prepared for  $\beta$ -galactosidase staining. Results presented in **FIG. 6** show increasingly weaker  $\beta$ -galactosidase activity in the brains of mice receiving  $\beta$ -galactosidase at 1, 5 and 10 minutes after injection of K16ApoE (SEQ ID NO: 22) and no visible staining thereafter. These results indicate that most of the injected K16ApoE (SEQ ID NO: 22) becomes bound with proteins and cells in the circulation, and this binding becomes virtually complete within 10 minutes after which no free K16ApoE (SEQ ID NO: 22) remains in circulation. Free K16ApoE (SEQ ID NO: 22) that remains at early time points becomes bound with beta-galactosidase and carries the enzyme in the brain. The peptide by itself and/or being bound with blood proteins/cells did not seem to affect the BBB as no  $\beta$ -galactosidase enzyme activity was seen in the brain from 10 min to 4 hours.

*Example 11- Necessity of covalent linking of hydrophilic amino acid chain and carrier peptide*

**[0101]** The necessity of covalent linking of the K16 (SEQ ID NO: 4) and ApoE (SEQ ID NO: 13) peptide moieties was evaluated for non-covalent transport of a protein across the BBB. For this,  $\beta$ -galactosidase was mixed with either the ApoE peptide, the peptide K16 (SEQ ID NO: 4), ApoE plus K16 (SEQ ID NO: 4) or with K16ApoE (SEQ ID NO: 22), and injected in mice. Brain sections from these mice show  $\beta$ -galactosidase staining only in slides from mice receiving  $\beta$ -galactosidase mixed with K16ApoE (SEQ ID NO: 22), indicating that linking of the K16 (SEQ ID NO: 4) and the ApoE peptide moieties is critical for transport of a protein in a non-covalent manner (**FIG. 7**).

*Example 12 - Testing mutant ApoE peptides for their potential as non-covalent transporters of proteins across the BBB*

**[0102]**  $\beta$ -galactosidase was mixed with equal amounts of various peptide transporters and injected into mice. Slides were prepared using 25  $\mu$ m sections of the mice brains one hour after injection followed by development of enzyme staining (**FIG. 8**). The following peptides were evaluated:

- A: KKKK KKKK KKKK KKKK LRLR LANH LRKL RKRL LRDA (SEQ ID NO: 126);
- B: KKKK KKKK KKKK KKKK LRLR LASH LRKL RKRL LRDL (SEQ ID NO: 127);
- C: KKKK KKKK KKKK KKKK LRVR LANH LRKL RKRL LRDL (SEQ ID NO: 128).

**[0103]** As shown in **FIG. 8**, mutant A was worse than the wild-type ApoE blood-brain barrier agent, while mutants B and C were able to transport the  $\beta$ -galactosidase at least as well as wild-type or better.

*Example 13 - Time course for  $\beta$ -galactosidase delivery in mouse brain with K16ApoE*

(SEQ ID NO: 22)

**[0104]** In each mouse, 1.38 nanomoles of  $\beta$ -galactosidase was mixed with 89 nanomoles of K16ApoE (SEQ ID NO:



22) and injected intravenously. 25  $\mu$ m brain slices were prepared for staining for  $\beta$ -galactosidase activity at indicated time points (**FIG. 9**). Figure 8 provides the following time points:

- A- Beta-galactosidase, no peptide, 6h.
- B- Beta-galactosidase+ peptide, 1h.
- C- Beta-galactosidase+ peptide, 2h.
- D- Beta-galactosidase+ peptide, 5h.
- E- Beta-galactosidase+ peptide, 10h.

# SEQUENCE LISTING

[0105]

<110> MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

<120> PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER

<130> 07039-0947W01

<140> PCT/US2010/041924

<141> 2010-07-13

<150> 61/225,412

<151> 2009-07-14

<160> 143

<170> PatentIn version 3.5

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 1

**Lys Lys Lys Lys**  
**1**

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 2

**Lys Lys Lys Lys Lys Lys Lys Lys**  
**1 5**

<210> 3

<211> 12

**EP 2 453 923 B1**

&lt;212&gt; PRT

### <213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: Synthetic peptide

<400> 3

$^{10}$

<210> 4

<211> 16

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20                      <400> 4

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

25            <210> 5

<211> 4

&lt;212&gt; PRT

### <213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 5

35 Arg Arg Arg Arg  
1

<210> 6

$\langle 211 \rangle$  8

40 <212> PRT

### <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

45

<400> 6

Arg Arg Arg Arg Arg Arg Arg Arg  
1 5

 $\langle 210 \rangle$  7

<211> 12

<212> PRT

<213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence: Synthetic peptide

EP 2 453 923 B1

<400> 7

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg  
1 5 10

5

<210> 8

<211> 16

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 8

15

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg  
1 5 10 15

<210> 9

20

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

25

<223> Description of Artificial Sequence: Synthetic peptide

<400> 9

30

Lys Arg Lys Arg  
1

<210> 10

<211> 4

<212> PRT

35

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

40

<400> 10

Lys Lys Lys Arg  
1

45

<210> 11

<211> 12

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 11

55

Lys Lys Lys Arg Arg Arg Lys Lys Lys Arg Arg Arg  
1 5 10

<210> 12

**EP 2 453 923 B1**

<211> 16

<212> PRT

### <213> Artificial Sequence

5                    <220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 12

<sup>10</sup>

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Lys | Lys | Lys | Arg | Arg | Arg | Arg | Lys | Lys | Lys | Lys | Arg | Arg | Arg | Arg |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

<210> 13

$\langle 211 \rangle$  20

15 <212> PRT

### <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20

<400> 13

Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
1 5 10 15

25

Leu Arg Asp Ala  
20

30                    <210> 14

<211> 40

<212> PRT

### <213> Artificial Sequence

35                      <220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 14

40

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ser | Val | Ile | Asp | Ala | Leu | Gln | Tyr | Lys | Leu | Glu | Gly | Thr | Thr | Arg |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

45

Asn Lys Phe Val Glu Gly Ser His  
35 40

50

<210> 15

<211> 36

<212> PRT

### <213> Artificial Sequence

55

 $\langle 220 \rangle$ 

<223> Description of Artificial Sequence: Synthetic polypeptide

# EP 2 453 923 B1

<220>  
 <221> MOD\_RES  
 <222> (36)..(36)  
 <223> Tyr or a Tyr derivative

5  
 <400> 15

10  
 Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu  
 1 5 10 15  
 Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr  
 20 25 30  
 15  
 Arg Gln Arg Xaa  
 35

20  
 <210> 16  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

25  
 <220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

30  
 <220>  
 <221> MOD\_RES  
 <222> (34)..(34)  
 <223> Tyr or a Tyr derivative  
 <400> 16

35  
 Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Ser  
 1 5 10 15  
 Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln  
 20 25 30  
 40  
 Arg Xaa

45  
 <210> 17  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

50  
 <220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

55  
 <220>  
 <221> MOD\_RES  
 <222> (36)..(36)  
 <223> Tyr or a Tyr derivative  
 <400> 17

# EP 2 453 923 B1

Tyr Pro Ser Asp Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp  
1 5 10 15

5 Leu Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr  
20 25 30

10 Arg Gln Arg Xaa  
35

<210> 18

<211> 36

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20 <220>

<221> MOD\_RES

<222> (36)..(36)

<223> Tyr or a Tyr derivative

25 <400> 18

Ala Pro Leu Glu Pro Val Tyr Pro Gly Asp Asp Ala Thr Pro Glu Gln  
1 5 10 15

30 Met Ala Gln Tyr Ala Ala Glu Leu Arg Arg Tyr Ile Asn Met Leu Thr  
20 25 30

35 Arg Pro Arg Xaa  
35

<210> 19

<211> 24

40 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

45 <400> 19

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu  
1 5 10 15

50 Arg Lys Arg Leu Leu Arg Asp Ala  
20

55 <210> 20

<211> 28

<212> PRT

<213> Artificial Sequence

# EP 2 453 923 B1

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 20

5

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
1 5 10 15

10

Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

<210> 21

<211> 32

15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20

<400> 21

25

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala

30

20

25

30

<210> 22

<211> 36

<212> PRT

35

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

40

<400> 22

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

45

Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

50

Leu Arg Asp Ala  
35

<210> 23

<211> 40

55

<212> PRT

<213> Artificial Sequence

<220>

# EP 2 453 923 B1

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 23

```

5      Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
      1          5          10          15

10     Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu
      20          25          30

15     Arg Lys Arg Leu Leu Arg Asp Ala
      35          40

```

<210> 24

<211> 44

<212> PRT

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 24

25

```

      Lys Lys Lys Lys Ser Ser Val Ile Asp Ala Leu Gln Tyr Lys Leu Glu
      1          5          10          15

30     Gly Thr Thr Arg Leu Thr Arg Lys Arg Gly Leu Lys Leu Ala Thr Ala
      20          25          30

      Leu Ser Leu Ser Asn Lys Phe Val Glu Gly Ser His
      35          40

```

35

<210> 25

<211> 48

<212> PRT

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 25

45

```

      Lys Lys Lys Lys Lys Lys Lys Lys Ser Ser Val Ile Asp Ala Leu Gln
      1          5          10          15

50     Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys Arg Gly Leu Lys
      20          25          30

      Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val Glu Gly Ser His
      35          40          45

```

55

<210> 26

<211> 52



# EP 2 453 923 B1

<212> PRT

<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 26

```

10      Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Ser Ser Val Ile
      1              5              10              15

      Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys
15              20              25              30

      Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val
              35              40              45

20      Glu Gly Ser His
              50
  
```

<210> 27

25 <211> 56

<212> PRT

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 27

```

35      Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
      1              5              10              15

      Ser Ser Val Ile Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg
              20              25              30

40      Leu Thr Arg Lys Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser
              35              40              45

45      Asn Lys Phe Val Glu Gly Ser His
              50              55
  
```

<210> 28

<211> 60

50 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

55

<400> 28

# EP 2 453 923 B1

|    |                                                             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-------------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Lys                                                         | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys | Lys |
|    | 1                                                           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |     | 15  |     |
| 5  | Lys                                                         | Lys | Lys | Lys | Ser | Ser | Val | Ile | Asp | Ala | Leu | Gln | Tyr | Lys | Leu | Glu |     |
|    |                                                             |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |     |
| 10 | Gly                                                         | Thr | Thr | Arg | Leu | Thr | Arg | Lys | Arg | Gly | Leu | Lys | Leu | Ala | Thr | Ala |     |
|    |                                                             |     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |     |
|    | Leu                                                         | Ser | Leu | Ser | Asn | Lys | Phe | Val | Glu | Gly | Ser | His |     |     |     |     |     |
|    | 50                                                          |     |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |     |
| 15 | <210> 29                                                    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <211> 20                                                    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <212> PRT                                                   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <213> Artificial Sequence                                   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 20 | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Description of Artificial Sequence: Synthetic peptide |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 25 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (3)..(3)                                              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Ala, Leu, Ser, or Val                                 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 30 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (5)..(5)                                              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Leu or Met                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 35 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (6)..(6)                                              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Ala or Ser                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 40 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (7)..(7)                                              |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Asn, Ser, or Thr                                      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 45 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (11)..(11)                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Lys or Asn                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 50 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (12)..(12)                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Leu, Met, or Val                                      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <220>                                                       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 55 | <221> MOD_RES                                               |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <222> (13)..(13)                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <223> Arg or Pro                                            |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

# EP 2 453 923 B1

<220>  
 <221> MOD\_RES  
 <222> (17)..(17)  
 <223> Leu or Met

5

<220>  
 <221> MOD\_RES  
 <222> (20)..(20)  
 <223> Ala or Leu

10

<400> 29

15

Leu Arg Xaa Arg Xaa Xaa Xaa His Leu Arg Xaa Xaa Xaa Lys Arg Leu  
 1 5 10 15

Xaa Arg Asp Xaa  
 20

20

<210> 30  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

25

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

<400> 30

30

Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
 1 5 10 15

35

Leu Arg Asp Ala  
 20

40

<210> 31  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

45

<400> 31

Leu Arg Val Arg Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
 1 5 10 15

50

Leu Arg Asp Ala  
 20

55

<210> 32  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

# EP 2 453 923 B1

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 32

5

Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu Arg Lys Arg Leu  
1 5 10 15

10

Leu Arg Asp Ala  
20

<210> 33

<211> 20

15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20

<400> 33

25

Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Pro Lys Arg Leu  
1 5 10 15

Leu Arg Asp Ala  
20

30

<210> 34

<211> 20

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 34

40

Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
1 5 10 15

Met Arg Asp Ala  
20

45

<210> 35

<211> 20

<212> PRT

50

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

55

<400> 35

EP 2 453 923 B1

Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu Arg Lys Arg Leu  
1 5 10 15

5 Leu Arg Asp Ala  
20

<210> 36

<211> 20

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

15

<400> 36

Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val Arg Lys Arg Leu  
1 5 10 15

20

Leu Arg Asp Ala  
20

25

<210> 37

<211> 20

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 37

35

Leu Arg Val Arg Met Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
1 5 10 15

40

Leu Arg Asp Ala  
20

<210> 38

<211> 20

<212> PRT

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

50

<400> 38

Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val Arg Lys Arg Leu  
1 5 10 15

55

Leu Arg Asp Ala  
20

<210> 39

# EP 2 453 923 B1

<211> 20  
<212> PRT  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence: Synthetic peptide  
  
<400> 39

10           Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Met Arg Lys Arg Leu  
              1                               5                               10                               15

15           Leu Arg Asp Ala  
                                  20

<210> 40  
<211> 20  
<212> PRT  
20 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide  
  
25 <400> 40

              Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
              1                               5                               10                               15

30           Leu Arg Asp Ala  
                                  20

35 <210> 41  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
40 <223> Description of Artificial Sequence: Synthetic peptide  
  
<400> 41

45           Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
              1                               5                               10                               15

              Met Arg Asp Ala  
                                  20

50 <210> 42  
<211> 20  
<212> PRT  
<213> Artificial Sequence

55 <220>  
<223> Description of Artificial Sequence: Synthetic peptide

EP 2 453 923 B1

<400> 42

5                   Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
                  1                   5                   10                   15

                  Met Arg Asp Ala  
                                  20

10           <210> 43  
              <211> 20  
              <212> PRT  
              <213> Artificial Sequence

15           <220>  
              <223> Description of Artificial Sequence: Synthetic peptide

<400> 43

20                   Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu Arg Lys Arg Leu  
                  1                   5                   10                   15

25                   Leu Arg Asp Ala  
                                  20

30           <210> 44  
              <211> 20  
              <212> PRT  
              <213> Artificial Sequence

              <220>  
              <223> Description of Artificial Sequence: Synthetic peptide

35           <400> 44

                  Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met Arg Lys Arg Leu  
                  1                   5                   10                   15

40                   Met Arg Asp Ala  
                                  20

45           <210> 45  
              <211> 20  
              <212> PRT  
              <213> Artificial Sequence

50           <220>  
              <223> Description of Artificial Sequence: Synthetic peptide

<400> 45

55

# EP 2 453 923 B1

Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu Pro Lys Arg Leu  
1 5 10 15

5 Leu Arg Asp Ala  
20

<210> 46

<211> 24

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

15

<400> 46

Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu  
1 5 10 15

20

Arg Lys Arg Leu Leu Arg Asp Ala  
20

25

<210> 47

<211> 28

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 47

35

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His  
1 5 10 15

Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

40

<210> 48

<211> 32

<212> PRT

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

50

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ser Arg  
1 5 10 15

55

Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30



# EP 2 453 923 B1

<210> 49  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

5

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

10

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 1 5 10 15

15

Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
 20 25 30

20

Leu Arg Asp Ala  
 35

<210> 50  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

25

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

30

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 1 5 10 15

35

Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu  
 20 25 30

40

Arg Lys Arg Leu Leu Arg Asp Ala  
 35 40

<210> 51  
 <211> 24  
 <212> PRT  
 <213> Artificial Sequence

45

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

50

<400>

Lys Lys Lys Lys Leu Arg Val Arg Met Ala Ser His Leu Arg Lys Leu  
 1 5 10 15

55

Arg Lys Arg Leu Leu Arg Asp Ala  
 20

# EP 2 453 923 B1

<210> 52  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

5

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

<400> 52

10

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Met Ala Ser His  
 1 5 10 15

15

Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
 20 25

<210> 53  
 <211> 32  
 <212> PRT  
 <213> Artificial Sequence

20

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

25

<400> 53

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
 1 5 10 15

30

Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
 20 25 30

<210> 54  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

35

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

40

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 1 5 10 15

45

Leu Arg Val Arg Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
 20 25 30

50

Leu Arg Asp Ala  
 35

<210> 55  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

55

# EP 2 453 923 B1

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 55

5

**Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys**  
**1 5 10 15**

10

**Lys Lys Lys Lys Leu Arg Val Arg Met Ala Ser His Leu Arg Lys Leu**  
**20 25 30**

15

**Arg Lys Arg Leu Leu Arg Asp Ala**  
**35 40**

<210> 56

<211> 24

<212> PRT

20

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

25

<400> 56

**Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu**  
**1 5 10 15**

30

**Arg Lys Arg Leu Leu Arg Asp Ala**  
**20**

<210> 57

35

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

40

<223> Description of Artificial Sequence: Synthetic peptide

<400> 57

**Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Thr His**  
**1 5 10 15**

45

**Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala**  
**20 25**

50

<210> 58

<211> 32

<212> PRT

<213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

# EP 2 453 923 B1

<400> 58

5                   Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
                  1                   5                   10                   15

                  Leu Ala Thr His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
                                  20                   25                   30

10           <210> 59  
              <211> 36  
              <212> PRT  
              <213> Artificial Sequence

15           <220>  
              <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 59

20                   Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
                  1                   5                   10                   15

25                   Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu Arg Lys Arg Leu  
                                  20                   25                   30

                  Leu Arg Asp Ala  
                                  35

30           <210> 60  
              <211> 40  
              <212> PRT  
              <213> Artificial Sequence

35           <220>  
              <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 60

40                   Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
                  1                   5                   10                   15

45                   Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Thr His Leu Arg Lys Leu  
                                  20                   25                   30

50                   Arg Lys Arg Leu Leu Arg Asp Ala  
                                  35                   40

55           <210> 61  
              <211> 24  
              <212> PRT  
              <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

EP 2 453 923 B1

<400> 61

5                   Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu  
                  1                   5                   10                   15

                  Pro Lys Arg Leu Leu Arg Asp Ala  
                                  20

10           <210> 62  
              <211> 28  
              <212> PRT  
              <213> Artificial Sequence

15           <220>  
              <223> Description of Artificial Sequence: Synthetic peptide

<400> 62

20                   Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
                  1                   5                   10                   15

                  Leu Arg Lys Leu Pro Lys Arg Leu Leu Arg Asp Ala  
                                  20                   25

25           <210> 63  
              <211> 32  
              <212> PRT  
              <213> Artificial Sequence

30           <220>  
              <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 63

35                   Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
                  1                   5                   10                   15

40                   Leu Ala Ser His Leu Arg Lys Leu Pro Lys Arg Leu Leu Arg Asp Ala  
                                  20                   25                   30

45           <210> 64  
              <211> 36  
              <212> PRT  
              <213> Artificial Sequence

50           <220>  
              <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 64

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Pro Lys Arg Leu  
20 25 30

10 Leu Arg Asp Ala  
35

<210> 65

<211> 40

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20 <400> 65

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

25 Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu  
20 25 30

30 Pro Lys Arg Leu Leu Arg Asp Ala

35

40

35 <210> 66

<211> 24

<212> PRT

<213> Artificial Sequence

40 <220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 66

45 Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu  
1 5 10 15

50 Arg Lys Arg Leu Met Arg Asp Ala  
20

<210> 67

<211> 28

<212> PRT

55 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

# EP 2 453 923 B1

<400> 67

5                   Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
                  1                   5                   10                   15

                  Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala  
                                  20                   25

10           <210> 68  
             <211> 32  
             <212> PRT  
             <213> Artificial Sequence

15           <220>  
             <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 68

20                   Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
                  1                   5                   10                   15

25                   Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala  
                                  20                   25                   30

30           <210> 69  
             <211> 36  
             <212> PRT  
             <213> Artificial Sequence

             <220>  
             <223> Description of Artificial Sequence: Synthetic polypeptide

35           <400> 69

                  Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
                  1                   5                   10                   15

40                   Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
                                  20                   25                   30

45                   Met Arg Asp Ala  
                                  35

50           <210> 70  
             <211> 40  
             <212> PRT  
             <213> Artificial Sequence

             <220>  
             <223> Description of Artificial Sequence: Synthetic polypeptide

55           <400> 70

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Leu  
20 25 30

10 Arg Lys Arg Leu Met Arg Asp Ala  
35 40

<210> 71

<211> 24

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20 <400> 71

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu  
1 5 10 15

25 Arg Lys Arg Leu Leu Arg Asp Ala  
20

<210> 72

30 <211> 28

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic peptide

<400> 72

40 Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
1 5 10 15

45 Leu Arg Asn Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

<210> 73

<211> 32

50 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

55 <400> 73



EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

5 Leu Ala Ser His Leu Arg Asn Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

<210> 74

<211> 36

10 <212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 74

20 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu Arg Lys Arg Leu  
20 25 30

25 Leu Arg Asp Ala  
35

<210> 75

30 <211> 40

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 75

40 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu  
20 25 30

45 Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

<210> 76

50 <211> 24

<212> PRT

<213> Artificial Sequence

<220>

55 <223> Description of Artificial Sequence: Synthetic peptide

<400> 76

# EP 2 453 923 B1

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val  
1 5 10 15

5 Arg Lys Arg Leu Leu Arg Asp Ala  
20

<210> 77

<211> 28

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

15

<400> 77

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
1 5 10 15

20

Leu Arg Lys Val Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

25

<210> 78

<211> 32

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 78

35

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

Leu Ala Ser His Leu Arg Lys Val Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

40

<210> 79

<211> 36

<212> PRT

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

50

<400> 79

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val Arg Lys Arg Leu  
20 25 30

10 Leu Arg Asp Ala  
35

<210> 80

<211> 40

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20 <400> 80

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

25 Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Val  
20 25 30

30 Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

<210> 81

<211> 24

35 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

40 <400> 81

Lys Lys Lys Lys Leu Arg Val Arg Met Ser Ser His Leu Arg Lys Leu  
1 5 10 15

45 Arg Lys Arg Leu Leu Arg Asp Ala  
20

50 <210> 82

<211> 28

<212> PRT

<213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 82

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Met Ser Ser His  
1 5 10 15

5 Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

<210> 83

<211> 32

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

15

<400> 83

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

20

Met Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

25

<210> 84

<211> 36

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 84

35

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

40

Leu Arg Val Arg Met Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

Leu Arg Asp Ala  
35

45

<210> 85

<211> 40

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 85

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Lys Lys Lys Lys Leu Arg Val Arg Met Ser Ser His Leu Arg Lys Leu  
20 25 30

Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

10

<210> 86

<211> 24

<212> PRT

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 86

20

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val  
1 5 10 15

25

Arg Lys Arg Leu Leu Arg Asp Ala  
20

<210> 87

<211> 28

30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

35

<400> 87

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
1 5 10 15

40

Leu Arg Asn Val Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

45

<210> 88

<211> 32

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 88

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

5 Leu Ala Ser His Leu Arg Asn Val Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

<210> 89

<211> 36

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

15

<400> 89

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

20

Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val Arg Lys Arg Leu  
20 25 30

25

Leu Arg Asp Ala  
35

<210> 90

30 <211> 40

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 90

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

40

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Val  
20 25 30

45

Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

50

<210> 91

<211> 24

<212> PRT

<213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 91

# EP 2 453 923 B1

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Met  
1 5 10 15

5 Arg Lys Arg Leu Leu Arg Asp Ala  
20

<210> 92

<211> 28

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

15

<400> 92

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
1 5 10 15

20

Leu Arg Asn Met Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

25

<210> 93

<211> 32

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 93

35

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

Leu Ala Ser His Leu Arg Asn Met Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

40

<210> 94

<211> 36

<212> PRT

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

50

<400> 94

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Met Arg Lys Arg Leu  
20 25 30

10 Leu Arg Asp Ala  
35

<210> 95

<211> 40

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20 <400> 95

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

25 Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Met  
20 25 30

30 Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

<210> 96

<211> 24

<212> PRT

35 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

40 <400> 96

Lys Lys Lys Lys Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu  
1 5 10 15

45 Arg Lys Arg Leu Leu Arg Asp Ala  
20

<210> 97

50 <211> 28

<212> PRT

<213> Artificial Sequence

<220>

55 <223> Description of Artificial Sequence: Synthetic peptide

<400> 97



# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ala Arg Met Ala Ser His  
1 5 10 15

5 Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

<210> 98

<211> 32

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

15

<400> 98

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ala Arg  
1 5 10 15

20

Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

25

<210> 99

<211> 36

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 99

35

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

40

Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

Leu Arg Asp Ala  
35

45

<210> 100

<211> 40

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 100

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Lys Lys Lys Lys Leu Arg Ala Arg Met Ala Ser His Leu Arg Lys Leu  
20 25 30

10 Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

<210> 101

<211> 24

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20 <400> 101

Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu  
1 5 10 15

25 Arg Lys Arg Leu Met Arg Asp Ala  
20

<210> 102

30 <211> 28

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic peptide

<400> 102

40 Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His  
1 5 10 15

Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala  
20 25

45 <210> 103

<211> 32

<212> PRT

<213> Artificial Sequence

50 <220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 103

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

5 Leu Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala  
20 25 30

<210> 104

<211> 36

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

15

<400> 104

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

20

Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

25

Met Arg Asp Ala  
35

<210> 105

30 <211> 40

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 105

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

40

Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Arg Lys Leu

45

20 25 30

Arg Lys Arg Leu Met Arg Asp Ala  
35 40

50

<210> 106

<211> 24

<212> PRT

<213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence: Synthetic peptide

# EP 2 453 923 B1

<400> 106

5                   Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu  
                  1                   5                   10                   15

                  Arg Lys Arg Leu Met Arg Asp Ala  
                                  20

10           <210> 107  
              <211> 28  
              <212> PRT  
              <213> Artificial Sequence

15           <220>  
              <223> Description of Artificial Sequence: Synthetic peptide

<400> 107

20                   Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His  
                  1                   5                   10                   15

25                   Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala  
                                  20                   25

              <210> 108  
              <211> 32  
              <212> PRT  
30           <213> Artificial Sequence  
  
              <220>  
              <223> Description of Artificial Sequence: Synthetic polypeptide

35           <400> 108

                  Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Ser Arg  
                  1                   5                   10                   15

40                   Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Met Arg Asp Ala  
                                  20                   25                   30

45           <210> 109  
              <211> 36  
              <212> PRT  
              <213> Artificial Sequence

50           <220>  
              <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 109

55

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

10 Met Arg Asp Ala  
35

<210> 110

<211> 40

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20 <400> 110

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

25 Lys Lys Lys Lys Leu Arg Ser Arg Leu Ala Ser His Leu Arg Lys Leu  
20 25 30

30 Arg Lys Arg Leu Met Arg Asp Ala  
35 40

<210> 111

<211> 24

35 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

40 <400> 111

Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu  
1 5 10 15

45 Arg Lys Arg Leu Leu Arg Asp Ala  
20

50 <210> 112

<211> 28

<212> PRT

<213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 112

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His  
1 5 10 15

5 Leu Pro Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25

<210> 113

<211> 32

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

15

<400> 113

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

20

Leu Ser Ser His Leu Pro Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala  
20 25 30

25

<210> 114

<211> 36

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 114

35

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

40

Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu Arg Lys Arg Leu  
20 25 30

Leu Arg Asp Ala  
35

45

<210> 115

<211> 40

<212> PRT

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 115

55

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

# EP 2 453 923 B1

Lys Lys Lys Lys Leu Arg Val Arg Leu Ser Ser His Leu Pro Lys Leu  
20 25 30

5 Arg Lys Arg Leu Leu Arg Asp Ala  
35 40

<210> 116

<211> 24

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

15

<400> 116

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met  
1 5 10 15

20

Arg Lys Arg Leu Met Arg Asp Ala  
20

25

<210> 117

<211> 28

<212> PRT

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 117

35

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
1 5 10 15

Leu Arg Lys Met Arg Lys Arg Leu Met Arg Asp Ala  
20 25

40

<210> 118

<211> 32

<212> PRT

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

50

<400> 118

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

55

Leu Ala Ser His Leu Arg Lys Met Arg Lys Arg Leu Met Arg Asp Ala  
20 25 30

# EP 2 453 923 B1

<210> 119  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

5

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

10

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 1 5 10 15

15

Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met Arg Lys Arg Leu  
 20 25 30

20

Met Arg Asp Ala  
 35

<210> 120  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

25

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

30

<400> 120

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 1 5 10 15

35

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Lys Met  
 20 25 30

40

Arg Lys Arg Leu Met Arg Asp Ala  
 35 40

<210> 121  
 <211> 24  
 <212> PRT  
 <213> Artificial Sequence

45

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

50

<400> 121

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu  
 1 5 10 15

55

Pro Lys Arg Leu Leu Arg Asp Ala  
 20



# EP 2 453 923 B1

<210> 122  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

5

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

<400> 122

10

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His  
 1 5 10 15

15

Leu Arg Asn Leu Pro Lys Arg Leu Leu Arg Asp Ala  
 20 25

<210> 123  
 <211> 32  
 <212> PRT  
 <213> Artificial Sequence

20

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

25

<400> 123

30

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
 1 5 10 15

Leu Ala Ser His Leu Arg Asn Leu Pro Lys Arg Leu Leu Arg Asp Ala  
 20 25 30

35

<210> 124  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

40

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 124

45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 1 5 10 15

50

Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu Pro Lys Arg Leu  
 20 25 30

Leu Arg Asp Ala  
 35

55

<210> 125  
 <211> 40  
 <212> PRT

# EP 2 453 923 B1

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

5

<400> 125

10

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Ser His Leu Arg Asn Leu  
20 25 30

15

Pro Lys Arg Leu Leu Arg Asp Ala  
35 40

<210> 126

<211> 36

20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

25

<400> 126

30

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Leu Arg Leu Arg Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

35

Leu Arg Asp Ala  
35

<210> 127

40

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

45

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 127

50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Leu Arg Leu Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

55

Leu Arg Asp Leu  
35

# EP 2 453 923 B1

<210> 128  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

5

<220>  
 <223> Description of Artificial Sequence: Synthetic polypeptide

<400> 128

10

**Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys**  
**1 5 10 15**

15

**Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg Leu**  
**20 25 30**

20

**Leu Arg Asp Leu**  
**35**

<210> 129  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

25

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

<400> 129

30

**Leu Arg Leu Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu**  
**1 5 10 15**

35

**Leu Arg Asp Leu**  
**20**

<210> 130  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

40

<220>  
 <223> Description of Artificial Sequence: Synthetic peptide

45

<400> 130

**Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg Leu**  
**1 5 10 15**

50

**Leu Arg Asp Leu**  
**20**

55

<210> 131  
 <211> 24  
 <212> PRT  
 <213> Artificial Sequence

# EP 2 453 923 B1

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 131

5

Lys Lys Lys Lys Leu Arg Leu Arg Leu Ala Ser His Leu Arg Lys Leu  
1 5 10 15

10

Arg Lys Arg Leu Leu Arg Asp Leu  
20

<210> 132

<211> 28

15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20

<400> 132

25

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Leu Arg Leu Ala Ser His  
1 5 10 15

Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Leu  
20 25

30

<210> 133

<211> 32

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<400> 133

40

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Leu Arg  
1 5 10 15

45

Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Leu  
20 25 30

<210> 134

<211> 36

<212> PRT

50

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

55

<400> 134

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Leu Arg Leu Arg Leu Ala Ser His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

10 Leu Arg Asp Leu  
35

<210> 135

<211> 40

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

20 <400> 135

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

25 Lys Lys Lys Lys Leu Arg Leu Arg Leu Ala Ser His Leu Arg Lys Leu  
20 25 30

30 Arg Lys Arg Leu Leu Arg Asp Leu  
35 40

<210> 136

<211> 24

35 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

40 <400> 136

Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu  
1 5 10 15

45 Arg Lys Arg Leu Leu Arg Asp Leu  
20

50 <210> 137

<211> 28

<212> PRT

<213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 137

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Asn His  
1 5 10 15

5 Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Leu  
20 25

<210> 138

<211> 32

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

15

<400> 138

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Leu Arg Val Arg  
1 5 10 15

20

Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Leu

25

20

25

30

<210> 139

<211> 36

<212> PRT

30 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

35

<400> 139

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

40

Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu Arg Lys Arg Leu  
20 25 30

45

Leu Arg Asp Leu  
35

<210> 140

<211> 40

50 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic polypeptide

55

<400> 140

# EP 2 453 923 B1

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

5 Lys Lys Lys Lys Leu Arg Val Arg Leu Ala Asn His Leu Arg Lys Leu  
20 25 30

10 Arg Lys Arg Leu Leu Arg Asp Leu  
35 40

<210> 141

<211> 20

<212> PRT

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

20 <400> 141

Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Leu Arg Lys Leu Arg Lys  
1 5 10 15

25 Arg Leu Leu Arg  
20

<210> 142

30 <211> 40

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<221> MOD\_RES

<222> (1)..(20)

40 <223> Hydrophilic amino acid and this region may encompass 4 to 20 residues

<220>

<221> MOD\_RES

<222> (23)..(23)

45 <223> Ala, Leu, Ser, or Val

<220>

<221> MOD\_RES

<222> (25)..(25)

50 <223> Leu or Met

<220>

<221> MOD\_RES

<222> (26)..(26)

55 <223> Ala or Ser

<220>

<221> MOD\_RES

<222> (27)..(27)

<223> Asn, Ser, or Thr

<220>

5 <221> MOD\_RES

<222> (31)..(31)

<223> Lys or Asn

<220>

10 <221> MOD\_RES

<222> (32)..(32)

<223> Leu, Met, or Val

<220>

15 <221> MOD\_RES

<222> (33)..(33)

<223> Arg or Pro

<220>

20 <221> MOD\_RES

<222> (37)..(37)

<223> Leu or Met

<220>

25 <221> MOD\_RES

<222> (40)..(40)

<223> Ala or Leu

<220>

30 <223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 142

35 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Xaa Xaa Xaa Leu Arg Xaa Arg Xaa Xaa Xaa His Leu Arg Xaa Xaa  
20 25 30

40

Xaa Lys Arg Leu Xaa Arg Asp Xaa  
35 40

45 <210> 143

<211> 70

<212> PRT

<213> Artificial Sequence

50 <220>

<223> Description of Artificial Sequence: Synthetic polypeptide

<220>

<221> MOD\_RES

55 <222> (1)..(50)

<223> Hydrophilic amino acid and this region may encompass 4 to 50 residues

<220>



<221> MOD\_RES  
 <222> (53)..(53)  
 <223> Ala, Leu, Ser, or Val

5       <220>  
       <221> MOD\_RES  
       <222> (55)..(55)  
       <223> Leu or Met

10       <220>  
       <221> MOD\_RES  
       <222> (56)..(56)  
       <223> Ala or Ser

15       <220>  
       <221> MOD\_RES  
       <222> (57)..(57)  
       <223> Asn, Ser, or Thr

20       <220>  
       <221> MOD\_RES  
       <222> (61)..(61)  
       <223> Lys or Asn

25       <220>  
       <221> MOD\_RES  
       <222> (62)..(62)  
       <223> Leu, Met, or Val

30       <220>  
       <221> MOD\_RES  
       <222> (63)..(63)  
       <223> Arg or Pro

35       <220>  
       <221> MOD\_RES  
       <222> (67)..(67)  
       <223> Leu or Met

40       <220>  
       <221> MOD\_RES  
       <222> (70)..(70)  
       <223> Ala or Leu

45       <220>  
       <223> see specification as filed for detailed description of substitutions and preferred embodiments  
       <400> 143

50

55

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

5 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
20 25 30

10 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
35 40 45

Xaa Xaa Leu Arg Xaa Arg Xaa Xaa Xaa His Leu Arg Xaa Xaa Xaa Lys  
50 55 60

15 Arg Leu Xaa Arg Asp Xaa  
65 70

## 20 Claims

1. A carrier peptide comprising the sequence:

25  $X_n-[B]_m$

or a pharmaceutically acceptable salt thereof, wherein:

30 X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3;

wherein the blood-brain barrier agent comprises a polypeptide sequence having at least 80% sequence identity to:

35 L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

2. The carrier peptide of claim 1, wherein each X is independently chosen from arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and tyrosine, or wherein n is chosen from 4, 8, 12, 16, and 20, or wherein m is 1.

3. The carrier peptide of claim 1, wherein the polypeptide is less than 100 amino acids in length.

4. The carrier peptide of claim 1, wherein the carrier peptide is chosen from:

45 K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:19);  
K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:20);  
K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:21);  
K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:22);  
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:23).

5. A complex, or a pharmaceutically acceptable salt thereof, comprising a biologically active molecule or an imaging agent associated with the carrier peptide of one of the preceding claims.


6. The complex of claim 5, wherein the imaging agent is chosen from:  $^{125}\text{I}$ -IgG and magnevist.

7. The complex of claim 5, wherein the biologically active molecule is chosen from a: polypeptide; oligonucleotide; plasmid; small molecule; antibody; antibody fragment; carbohydrate; polysaccharide; lipid; glycolipid; antigen; and antigenic peptide, in particular wherein the oligonucleotide is chosen from a: coding DNA sequence; antisense DNA

sequence; mRNA, antisense RNA sequence; RNAi; and siRNA, or wherein the small molecule is a therapeutic agent.

8. The complex of claim 5, wherein the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide.

9. A complex, or a pharmaceutically acceptable salt thereof, comprising a biologically active agent associated with a carrier peptide, wherein the carrier peptide comprises the sequence:




wherein:

X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3,

wherein the blood-brain barrier agent comprises a polypeptide sequence having at least 80% sequence identity to: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13), for use in treating brain disorder, in particular wherein the brain disorder is chosen from: meningitis, epilepsy, multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, Parkinson's, progressive multifocal leukoencephalopathy, De Vivo disease, Alzheimer's disease, HIV Encephalitis, and cancer.

10. A method of imaging the central nervous system of a subject, the method comprising administering to the subject a complex, or a pharmaceutically acceptable salt thereof, comprising an imaging agent associated with a carrier peptide, wherein the carrier peptide comprises the sequence:




wherein:

X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3; and  
imaging the central nervous system of the subject,

wherein the blood-brain barrier agent comprises a polypeptide sequence having at least 80% sequence identity to: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13)..

11. A pharmaceutical composition comprising a complex, or a pharmaceutically acceptable salt thereof, comprising a biologically active molecule or imaging agent, a carrier peptide, and a pharmaceutically acceptable carrier; wherein the carrier peptide comprises the sequence:




wherein:

X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3,

wherein the blood-brain barrier agent comprises a polypeptide sequence having at least 80% sequence identity to: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13)..

12. A kit comprising a carrier peptide, wherein the carrier peptide comprises the sequence:



or a pharmaceutically acceptable salt thereof, wherein:

- 5 X is a hydrophilic amino acid;  
B is a blood-brain barrier agent;  
n is an integer from 4 to 50; and  
m is integer from 1 to 3,

10 wherein the blood-brain barrier agent comprises a polypeptide sequence having at least 80% sequence identity to:  
L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).,  
wherein the kit further comprises a biologically active molecule or an imaging agent.

## 15 Patentansprüche

1. Trägerpeptid, welches die Sequenz:



20 umfasst, oder ein pharmazeutisch unbedenkliches Salz davon, wobei:

- X für eine hydrophile Aminosäure steht;  
B für ein Blut-Hirn-Barrieremittel steht;  
25 n für eine ganze Zahl von 4 bis 50 steht und  
m für eine ganze Zahl von 1 bis 3 steht,

wobei das Blut-Hirn-Barrieremittel eine Polypeptidsequenz mit mindestens 80% Sequenzidentität zu:

30 L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 13)

umfasst.

35 2. Trägerpeptid nach Anspruch 1, wobei X unabhängig aus Arginin, Asparagin, Asparaginsäure, Glutaminsäure, Glutamin, Histidin, Lysin, Serin, Threonin und Tyrosin ausgewählt ist oder wobei n aus 4, 8, 12, 16 und 20 ausgewählt ist oder wobei m für 1 steht.

3. Trägerpeptid nach Anspruch 1, wobei das Polypeptid eine Länge von weniger als 100 Aminosäuren aufweist.

40 4. Trägerpeptid nach Anspruch 1, wobei das Trägerpeptid ausgewählt ist aus: K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 19),

K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 20)  
K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 21),  
45 K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 22),  
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 23).

5. Komplex oder pharmazeutisch unbedenkliches Salz davon, umfassend ein biologisch aktives Molekül oder ein bilddarstellendes Mittel, assoziiert mit dem Trägerpeptid eines der vorhergehenden Ansprüche.

50 6. Komplex nach Anspruch 5, wobei das bilddarstellende Mittel ausgewählt ist aus: <sup>125</sup>I-IgG und Magnevist.

7. Komplex nach Anspruch 5, wobei das biologisch aktive Molekül ausgewählt ist aus einem: Polypeptid, Oligonukleotid, Plasmid, niedermolekularen Molekül, Antikörper, Antikörperfragment, Kohlenhydrat, Polysaccharid, Lipid, Glykolipid, Antigen und antigenen Peptid, wobei das Oligonukleotid insbesondere ausgewählt ist aus einer: codierenden DNA-Sequenz, antisense-DNA-Sequenz, mRNA, antisense-RNA-Sequenz, RNAi und siRNA, oder wobei es sich bei dem niedermolekularen Molekül um ein Therapeutikum handelt.

8. Komplex nach Anspruch 5, wobei das biologisch aktive Molekül oder bilddarstellende Mittel nichtkovalent an das Trägerpeptid gebunden ist.

9. Komplex oder pharmazeutisch unbedenkliches Salz davon, umfassend ein mit einem Trägerpeptid assoziiertes biologisch aktives Mittel, wobei das Trägerpeptid die Sequenz:



umfasst, wobei:

X für eine hydrophile Aminosäure steht,  
B für ein Blut-Hirn-Barrieremittel steht,  
n für eine ganze Zahl von 4 bis 50 steht und  
m für eine ganze Zahl von 1 bis 3 steht,

wobei das Blut-Hirn-Barrieremittel eine Polypeptidsequenz mit mindestens 80% Sequenzidentität zu: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 13) umfasst, zur Verwendung bei der Behandlung einer Hirnerkrankung, wobei die Hirnerkrankung insbesondere ausgewählt ist aus: Meningitis, Epilepsie, multipler Sklerose, Neuromyelitis optica, neurologischer Trypanosomiasis im Spätstadium, Parkinson-Krankheit, progressiver multifokaler Leukoencephalopathie, De-Vivo-Krankheit, Alzheimer-Krankheit, HIV-Enzephalitis und Krebs.

10. Verfahren zur bildlichen Darstellung des zentralen Nervensystems eines Patienten, wobei man bei dem Verfahren dem Patienten einen Komplex oder ein pharmazeutisch unbedenkliches Salz davon verabreicht, welcher bzw. welches ein mit einem Trägerpeptid assoziiertes bilddarstellendes Mittel umfasst, wobei das Trägerpeptid die Sequenz:



umfasst, wobei:

X für eine hydrophile Aminosäure steht;  
B für ein Blut-Hirn-Barrieremittel steht;  
n für eine ganze Zahl von 4 bis 50 steht und  
m für eine ganze Zahl von 1 bis 3 steht, und  
das zentrale Nervensystem des Patienten bildlich darstellt,

wobei das Blut-Hirn-Barrieremittel eine Polypeptidsequenz mit mindestens 80% Sequenzidentität zu:

L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 13)

umfasst.

11. Pharmazeutische Zusammensetzung, umfassend einen Komplex oder ein pharmazeutisch unbedenkliches Salz davon, welcher bzw. welches ein biologisch aktives Molekül oder bilddarstellendes Mittel, ein Trägerpeptid und einen pharmazeutisch unbedenklichen Träger umfasst, wobei das Trägerpeptid die Sequenz:



umfasst, wobei:

X für eine hydrophile Aminosäure steht;  
B für ein Blut-Hirn-Barrieremittel steht;  
n für eine ganze Zahl von 4 bis 50 steht und  
m für eine ganze Zahl von 1 bis 3 steht,

wobei das Blut-Hirn-Barrieremittel eine Polypeptidsequenz mit mindestens 80% Sequenzidentität zu: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 13) umfasst.

12. Kit, umfassend ein Trägerpeptid, wobei das Trägerpeptid die Sequenz:



umfasst, oder ein pharmazeutisch unbedenkliches Salz davon, wobei:

X für eine hydrophile Aminosäure steht;  
B für ein Blut-Hirn-Barrieremittel steht;  
n für eine ganze Zahl von 4 bis 50 steht und  
m für eine ganze Zahl von 1 bis 3 steht,


wobei das Blut-Hirn-Barrieremittel eine Polypeptidsequenz mit mindestens 80% Sequenzidentität zu: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO: 13)

umfasst,

wobei das Kit weiterhin ein biologisch aktives Molekül oder ein bilddarstellendes Mittel umfasst.

## Revendications

1. Peptide vecteur comprenant la séquence:



ou un sel pharmaceutiquement acceptable de celle-ci, où :

X est un acide aminé hydrophile ;  
B est un agent capable de traverser la barrière hémato-encéphalique ;  
n est un nombre entier valant de 4 à 50 ; et  
m est un nombre entier valant de 1 à 3 ;

dans lequel l'agent capable de traverser la barrière hémato-encéphalique comprend une séquence de polypeptide ayant une identité de séquence d'au moins 80 % avec :

L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

2. Peptide vecteur selon la revendication 1, dans lequel chaque X est choisi indépendamment parmi l'arginine, l'asparagine, l'acide aspartique, l'acide glutamique, la glutamine, l'histidine, la lysine, la sérine, la thréonine et la tyrosine, ou dans lequel n est choisi parmi 4, 8, 12, 16 et 20, ou dans lequel m est 1.

3. Peptide vecteur selon la revendication 1, dans lequel le polypeptide a une longueur de moins de 100 acides aminés.

4. Peptide vecteur selon la revendication 1, le peptide vecteur étant choisi parmi :

K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:19) ;  
K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:20) ;  
K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:21) ;  
K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:22) ;  
K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:23).

5. Complexe, ou sel pharmaceutiquement acceptable de celui-ci, comprenant une molécule biologiquement active ou un agent d'imagerie associé(e) au peptide vecteur selon l'une quelconque des revendications précédentes.


6. Complexe selon la revendication 5, dans lequel l'agent d'imagerie est choisi parmi : <sup>125</sup>I-IgG et Magnevist.

7. Complexe selon la revendication 5, dans lequel la molécule biologiquement active est choisie parmi : un polypeptide ; un oligonucléotide ; un plasmide ; une petite molécule ; un anticorps ; un fragment d'anticorps ; un glucide ; un polysaccharide ; un lipide ; un glycolipide ; un antigène ; et un peptide antigénique, en particulier dans lequel l'oligonucléotide est choisi parmi : une séquence d'ADN codant ; une séquence d'ADN antisens ; un ARNm, une sé-

quence d'ARN antisens, un ARNi ; et un ARNsi, ou dans lequel la petite molécule est un agent thérapeutique.

8. Complexe selon la revendication 5, dans lequel la molécule biologiquement active ou l'agent d'imagerie est lié(e) par une liaison non covalente au peptide vecteur.

9. Complexe, ou sel pharmaceutiquement acceptable de celui-ci, comprenant un agent biologiquement actif associé à un peptide vecteur, dans lequel le peptide vecteur comprend la séquence :



où :

X est un acide aminé hydrophile ;


B est un agent capable de traverser la barrière hémato-encéphalique ;

n est un nombre entier valant de 4 à 50 ; et

m est un nombre entier valant de 1 à 3,

dans lequel l'agent capable de traverser la barrière hémato-encéphalique comprend une séquence de polypeptide ayant une identité de séquence d'au moins 80 % avec: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13), pour utilisation dans le traitement d'une affection cérébrale, en particulier l'affection cérébrale étant choisie parmi : la méningite, l'épilepsie, la sclérose en plaques, la neuro-myélite optique, la trypanosomiase neurologique de stade avancé, la maladie de Parkinson, la leucoencéphalopathie multifocale progressive, la maladie de De Vivo, la maladie d'Alzheimer, l'encéphalite à VIH et le cancer.

10. Procédé d'imagerie du système nerveux central d'un sujet, le procédé comprenant l'administration au sujet d'un complexe, ou d'un sel pharmaceutiquement acceptable de celui-ci, comprenant un agent d'imagerie associé à un peptide vecteur, le peptide vecteur comprenant la séquence :



où :

X est un acide aminé hydrophile ;

B est un agent capable de traverser la barrière hémato-encéphalique ;


n est un nombre entier valant de 4 à 50 ; et

m est un nombre entier valant de 1 à 3 ; et

la visualisation du système nerveux du sujet ;

l'agent capable de traverser la barrière hémato-encéphalique comprenant une séquence de polypeptide ayant une identité de séquence d'au moins 80 % avec : L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

11. Composition pharmaceutique comprenant un complexe, ou un sel pharmaceutiquement acceptable de celui-ci, comprenant une molécule biologiquement active ou un agent d'imagerie, un peptide vecteur et un véhicule pharmaceutiquement acceptable, dans laquelle le peptide vecteur comprend la séquence :



où :

X est un acide aminé hydrophile ;


B est un agent capable de traverser la barrière hémato-encéphalique ;

n est un nombre entier valant de 4 à 50 ; et

m est un nombre entier valant de 1 à 3,

l'agent capable de traverser la barrière hémato-encéphalique comprenant une séquence de polypeptide ayant une identité de séquence d'au moins 80 % avec : L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

12. Nécessaire comprenant un peptide vecteur, dans lequel le peptide vecteur comprend la séquence :



ou un sel pharmaceutiquement acceptable de celle-ci, où :

X est un acide aminé hydrophile ;

B est un agent capable de traverser la barrière hémato-encéphalique ;

n est un nombre entier valant de 4 à 50 ; et

m est un nombre entier valant de 1 à 3,

l'agent capable de traverser la barrière hémato-encéphalique comprenant une séquence de polypeptide ayant une identité de séquence d'au moins 80 % avec : L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13), le nécessaire comprenant en outre une molécule biologiquement active ou un agent d'imagerie.







FIG. 1



**FIG. 2**




FIG. 3




FIG. 4




FIG. 5





FIG. 6



**FIG. 7**




FIG. 8






FIG. 9

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description


- US 2004229219 A1 [0004]
- US 5591721 A, Agrawal [0038]
- US 5652356 A, Agrawal [0038]
- WO 0044895 A, Kreutzer [0039]
- WO 0136646 A, Zernicka-Goetz [0039]
- WO 9932619 A, Fire [0039]
- WO 0001846 A, Plaetinck [0039]
- WO 0129058 A, Mello and Fire [0039]
- WO 9907409 A, Deschamps-Depaillette [0039]
- WO 0044914 A, Li [0039]
- US 4647447 A [0043]
- US 2010041924 W [0105]
- US 61225412 A [0105]

## Non-patent literature cited in the description

- **MOUSAZADEH MOHAMMAD et al.** *JOURNAL OF DRUG TARGETING*, 2007, vol. 15 (3), 226-230 [0003]
- **CHENNA et al.** *Nucleic Acids Res.*, 2003, vol. 31 (13), 3497-500 [0026]
- **PARDRIDGE, W.M.** *Bioconjug. Chem.*, 2008, vol. 19 (7), 1327-38 [0032]
- **EGHOLM et al.** *Nature*, 1993, vol. 365, 566 [0038]
- **STEIN ; CHENG.** *Science*, 1993, vol. 261, 1004 [0038]
- **ELBASHIR et al.** *Nature*, 2001, vol. 411, 494-498 [0039]
- **BASS.** *Nature*, 2001, vol. 411, 428-429 [0039]
- **Radiocontrast Agents.** Springer-Verlag, 1984, 23-125 [0043]
- **TYLER et al.** *Ultrasonic Imaging*, 1981, vol. 3, 323-29 [0044]
- **D. P. SWANSON.** Enhancement Agents for Ultrasound: Fundamentals. *Pharmaceuticals in Medical Imaging*, 1990, 682-87 [0044]
- **RAYUDU GVS.** *Radiotracers for Medical Applications*, vol. I, 201 [0045]
- **Pharmaceuticals in Medical Imaging.** 1990, 279-644 [0045]
- **P. H. STAHL ; C. G. WERMUTH.** Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, 2002 [0056]
- **Remington's Pharmaceutical Sciences.** Mack Publishing Co, 1990 [0064]
- **Ansel Introduction to Pharmaceutical Dosage Forms.** 1995, 126 [0070]
- **REMINGTON'S.** Pharmaceutical Sciences. Mack Publishing Company, 1975 [0075]

## Szabadalmi igénypontok

1. Hordozópeptid, amely tartalmazza a következő szekvenciát:



vagy gyógyászatiilag elfogadható sója, ahol:

X jelentése hidrofíl aminosav;

B jelentése véragyagáton átjuttató anyag ;

n értéke 4-50-ig bármely egész szám; és

m értéke 1-3-ig bármely egész szám;

ahol a véragyagáton átjuttató anyag tartalmaz polipeptid-szekvenciát, amely legalább 80% szekvenciaazonosságot mutat a következővel :

L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

2. Az 1. igénypont szerinti hordozópeptid, amelyben mindegyik X egymástól függetlenül a következő aminosavak közül választott:

arginin, aszparagin, aszparaginsav, glutaminsav, glutamin, hisztidin, lizin, szerin, treonin és tirozín, vagy ahol n értéke a következők közül választott: 4, 8, 12, 16 és 20, vagy ahol m értéke 1.

3. Az 1. igénypont szerinti hordozópeptid, ahol a polipeptid kevesebb, mint 100 aminosav hosszúságú.

4. Az 1. igénypont szerinti hordozópeptid, ahol a hordozópeptid a következők közül választott:

K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:19);

K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:20);

K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:21);

K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:22);

K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-K-L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:23).

5. Komplex vagy annak gyógyászatiilag elfogadható sója, amely biológiailag aktív molekulát vagy kontrasztanyagot tartalmaz az előző igénypontok bármelyike szerinti hordozópeptidhez kapcsoltn.


6. Az 5. igénypont szerinti komplex, amelyben a kontrasztanyag  $^{125}\text{I}$ -IgG és magneviszt közül választott.

7. Az 5. igénypont szerinti komplex, amelyben a biológiailag aktív molekula a következők közül választott: polipeptid, oligonukleotid, plazmid, kis molekula, antitest, antitestfragmens, szénhidrát, polisacharid, lipid, glikolipid, antigén, antigénpeptid, különösen ahol az oligonukleotid a következők közül választott: kódoló DNS-szekvencia, antiszensz DNS-szekvencia, mRNS, antiszensz RNS-szekvencia, RNSi valamint siRNS vagy ahol a kis molekula terápiás szer.

8. Az 5. igénypont szerinti komplex, amelyben a biológiailag aktív molekula vagy kontrasztanyag nem

kovalensen a hordozópeptidhez kötött.

9. Komplex vagy gyógyászatilag elfogadható sója, amely hordozópeptidhez kapcsoltan biológiailag aktív anyagot tartalmaz, ahol a hordozópeptid tartalmazza a következő szekvenciát:



ahol:

X jelentése hidrofíil aminosav;

B jelentése véragyagáton átjuttató anyag;


n értéke 4-50-ig bármely egész szám; és

m értéke 1-3-ig bármely egész szám;

ahol a véragyagáton átjuttató anyag tartalmaz polipeptid-szekvenciát, amely legalább 80% szekvenciaazonosságot mutat a következővel: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13),

agyi rendellenesség kezelésében való alkalmazásra, különösen ahol az agyi rendellenesség a következők közül választott: meningitisz, epilepszia, szklerózis multiplex, neuromyelitis optica, késői stádiumú idegrendszeri tripanosomiázis, Parkinson-kór, progresszív multifokális leukoencefalopátia, De Vivo betegség, Alzheimer-kór, HIV-encefalitisz és rák.

10. Eljárás képalkotásra személy központi idegrendszeréről, amely eljárás tartalmazza a személy részére olyan komplex vagy gyógyászatilag elfogadható sója beadását, amely hordozópeptidhez kapcsolódó kontrasztanyagot tartalmaz, amely hordozópeptid tartalmazza a következő szekvenciát:



ahol:

X jelentése hidrofíil aminosav;


B jelentése véragyagáton átjuttató anyag;

n értéke 4-50-ig bármely egész szám; és

m értéke 1-3-ig bármely egész szám;

ahol a véragyagáton átjuttató anyag tartalmaz polipeptid-szekvenciát, amely legalább 80% szekvenciaazonosságot mutat a következővel: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

11. Gyógyászati készítmény, amely komplexet tartalmaz vagy annak gyógyászatilag elfogadható sóját tartalmazza, amely biológiailag aktív molekulát vagy kontrasztanyagot, hordozópeptidet és gyógyászatilag elfogadható hordozót tartalmaz, ahol a hordozópeptid tartalmazza a következő szekvenciát:



ahol:

X jelentése hidrofíil aminosav;


B jelentése véragyagáton átjuttató anyag;

n értéke 4-50-ig bármely egész szám; és

m értéke 1-3-ig bármely egész szám;

ahol a véragyagáton átjuttató anyag tartalmaz polipeptid-szekvenciát, amely legalább 80% szekvenciaazonosságot mutat a következővel: L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).

12. Reagenskészlet, amely hordozópeptidet tartalmaz, amely hordozópeptid tartalmazza a következő szekvenciát:



vagy gyógyászatiilag elfogadható sója, ahol:

X jelentése hidrofil aminosav;

B jelentése véragyagáton átjuttató anyag;

n értéke 4-50-ig bármely egész szám; és

m értéke 1-3-ig bármely egész szám;

ahol a véragyagáton átjuttató anyag tartalmaz polipeptid-szekvenciát, amely legalább 80% szekvenciaazonosságot mutat a következővel : L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A (SEQ ID NO:13).